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current evidence that Mrp4 regulates testosterone biosynthesis. The role of Mrp4 was investigated in
Leydig cells where testosterone production is regulated by cAMP, an intracellular second messenger
formed when the luteinizing hormone (LH) receptor (Lhr) is activated. As Mrp4 regulates cAMP, we
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reduced testicular testosterone, impaired gametogenesis, and disrupted cAMP homeostasis, resulting in
decreased expression of genes involved in testosterone biosynthesis. Testosterone production was also
impaired in adult KO mice but testicular morphology was normal. In vitro culture of primary KO Leydig
cells stimulated with LH revealed decreased intracellular cAMP concentrations and attenuated cAMPresponse element binding protein (CREB) phosphorylation of downstream targets, notably several genes
directly involved in testosterone biosynthesis. However, chemical inhibition of Mrp4 in WT Leydig cells
revealed a substantial elevation in intracellular cAMP concentration but paradoxically reduced
testosterone production. The reduced testosterone production was related to decreased immunoreactive
StAR expression, the rate limiting step in testosterone biosynthesis. Future analysis will focus on the
mechanism controlling cAMP concentrations under these conditions, with a primary focus on cAMP
regulation by phosphodiesterases (PDEs). Continued assessment of our KO animals revealed prepubertal animals had reduced systemic testosterone concentrations while adult mice had normal
circulating levels. The difference is pre-pubertal KO mice have increased Cyp2b10, a known testosterone
metabolizing enzyme, expression and catalytic activity due to disrupted testicular testosterone
production. Therefore, defective testicular testosterone production deregulates hepatic Cyp-mediated
testosterone metabolism to disrupt gametogenesis. The findings presented here have important
implications for understanding the side effects of therapeutics that disrupt Mrp4 function and can alter
androgen production.
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ABSTRACT
The physiological role of multidrug resistance protein 4 (Mrp4) in the testes is
unknown. It was discovered that Mrp4 is expressed primarily in mouse and human
Leydig cells; however, there is no current evidence that Mrp4 regulates testosterone
biosynthesis. The role of Mrp4 was investigated in Leydig cells where testosterone
production is regulated by cAMP, an intracellular second messenger formed when the
luteinizing hormone (LH) receptor (Lhr) is activated. As Mrp4 regulates cAMP, we
compared testosterone levels in our Mrp4 WT and KO mice. Pre-pubertal KO mice had
significantly reduced testicular testosterone, impaired gametogenesis, and disrupted
cAMP homeostasis, resulting in decreased expression of genes involved in testosterone
biosynthesis. Testosterone production was also impaired in adult KO mice but testicular
morphology was normal. In vitro culture of primary KO Leydig cells stimulated with LH
revealed decreased intracellular cAMP concentrations and attenuated cAMP-response
element binding protein (CREB) phosphorylation of downstream targets, notably several
genes directly involved in testosterone biosynthesis. However, chemical inhibition of
Mrp4 in WT Leydig cells revealed a substantial elevation in intracellular cAMP
concentration but paradoxically reduced testosterone production. The reduced
testosterone production was related to decreased immunoreactive StAR expression, the
rate limiting step in testosterone biosynthesis. Future analysis will focus on the
mechanism controlling cAMP concentrations under these conditions, with a primary
focus on cAMP regulation by phosphodiesterases (PDEs).
Continued assessment of our KO animals revealed pre-pubertal animals had
reduced systemic testosterone concentrations while adult mice had normal circulating
levels. The difference is pre-pubertal KO mice have increased Cyp2b10, a known
testosterone metabolizing enzyme, expression and catalytic activity due to disrupted
testicular testosterone production. Therefore, defective testicular testosterone production
deregulates hepatic Cyp-mediated testosterone metabolism to disrupt gametogenesis.
The findings presented here have important implications for understanding the side
effects of therapeutics that disrupt Mrp4 function and can alter androgen production.
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CHAPTER 1.

INTRODUCTION

ABC Transporters
By definition, ATP-binding cassette (ABC) transporters are responsible for
mediating the adenosine triphosphate (ATP) dependent unidirectional exclusion of both
endogenous and exogenous compounds across membranes [1]. In 1976, the first member
of the ABC transporter superfamily was identified. Ling and others described a 170 kD
membrane glycoprotein overexpressed in colchicine resistant cell lines and termed it Pgp, a glycoprotein responsible for reducing drug permeability [2]. Over 15 years later,
two additional ABC transporters were identified. The first was ABCC1, discovered by
the laboratories of Cole and Deeley [3] while the second, ABCG2, was identified by three
independent laboratories almost simultaneously [4-6]. Currently, these three transporters
are considered to be the major drug transporters that contribute to the multidrug
resistance phenotype observed in multiple tumors and cell lines [7], a phenomenon
described as the simultaneous resistance to several structurally unrelated drugs that do not
have a common mechanism of action [8].
While P-GP, ABCC1 and ABCG2 were the first transporters identified, there are
currently 48 human ABC transporters described, each classified into seven separate
subfamilies (ABCA-ABCG) based on the sequence and organization of their ATP
binding domains [9]. As ABC transporters are either localized to the plasma membrane
or to the membranes of intracellular organelles, they function to move compounds from
the cytoplasm to outside the cell or into an intracellular compartment such as the
endoplasmic reticulum, mitochondria or peroxisomes [9]. These transporters serve a
wide variety of cellular roles such as regulating permeability by being expressed in the
blood-brain barrier, blood cerebrospinal fluid, blood-testes barrier, and the placenta [10].
ABC transporters play a protective role by their ability to excrete toxins in such organs as
the liver, kidney and gastrointestinal tract [11]. Additionally, they serve physiological
roles in cellular lipid transport and maintenance of homeostasis [12]. With their broad
expression pattern and functional capabilities, ABC transporters serve a wide variety of
important physiological functions (Table 1-1).
Structurally, ABC transporters are comprised of two nucleotide binding domains
(NBDs) and two transmembrane binding domains (TMDs), encoded by a single
polypeptide [13]. The NBDs contains the ATP binding domains while the substrate
binding domains are located within the TMDs. Within the NBDs are the characteristic
Walker A and Walker B motifs, separated by approximately 90-120 amino acids. ABC
proteins also contain an additional element, the signature C motif, located just upstream
of the Walker B site [13]. The TMDs contain 6-11 membrane spanning D-helices while
the NBDs are located in the cytoplasm. ABC transporters are classified as full
transporters if they contain two core units in tandem (TMD-NBD-TMD-NBD) that are
active alone, or they are half transporters when only one core unit is present (TMDNBD). In the case of half transporters, they must form obligate homo- or hetero-dimers
for activation [14].
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Table 1-1.

Localization and function of representative ABC transporters.

Transporter Expression

Function

ABCA1

Ubiquitous

Cholesterol efflux to HDL [15]

ABCA6

Ubiquitous

Macrophage lipid homeostasis [16]

ABCA12

Lamellar granules/bodies

Lipid metabolism [17]

ABCB6

Mitochondria

Heme transport and biosynthesis [18]

ABCB9

Testes, brain, spinal cord

Peptide transport [19]

ABCB11

Liver

Bile salt transport [20]

ABCC1

Lung, testes, peripheral blood Organic anion transporter [21]

ABCC4

Multiple tissues

Drug resistance [22, 23]

ABCC7

Exocrine tissues

Chloride ion channel [24]

ABCC9

Skeletal muscle, heart

K(ATP) channel regulation [25]

ABCD3

Peroxisomes

Peroxisome biogenesis [26]

ABCG2

Liver, intestine, breast

Vitamin B2 pump, heme efflux [27, 28]

ABCG5

Liver, small intestine

Sterol transport [29]
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The Multi-drug Resistance Protein 4 (MRP4)
MRP4 (ABCC4) is a member of the C subfamily of ABC transporters. The gene
is located on chromosome 13q32.1, and at 1325 amino acids in length, is the shortest
member of this family. It is a full transporter, comprised of two TMD and two NBD
(Figure 1-1). The first functional properties of MRP4 were described in 1999 by
Schuetz, et al using a human T-lymphoid cell line in which MRP4 overexpression was
directly linked to impaired antiviral efficacy and increased efflux of antiviral nucleoside
based drugs [30]. In vitro, MRP4 possesses the unique characteristic of being able to
export a wide range of structurally diverse compounds. MRP4 has been shown to
transport endogenous molecules that play key roles in cellular communication and
signaling, including cyclic nucleotides, eicosanoids, adenosine diphosphate, and
conjugated steroid hormones [31]. Other physiologically relevant substrates include
folate, bile acids and glutathione, which are co-transported with bile acids [32-34]. In
addition to endogenous substrates, MRP4 also transports a broad range of drug substrates
including antivirals (adefovir [35] and tenofovir [36]), antibiotics (cefalosporins [37]) and
cytotoxic agents (methotrexate [33], topotecan [38], 6-thioguanine and 6-mercaptopurine
[39].
MRP4 is also unique from other C subfamily members by its ability to have dual
membrane localization in polarized cell types. In renal proximal tubule cells, MRP4 is
localized to the apical side of the membrane [23] whereas it is located in the basolateral
membrane in prostate tubuloacinar cells [40] and choroid plexus epithelium [38].
Interestingly, in a colonic epithelial cell line, protein expression was seen in both the
apical and basolateral membrane, with increased abundance on the apical side [41].
Development of the Mrp4 KO mouse
While in vitro studies have been crucial for understanding the transport function,
substrates and membrane localization of MRP4, it was the development of the Mrp4 KO
mouse model that derived both the physiological and pharmacological roles of this
transporter. Engineered by Leggas, et al, the mouse was generated as follows. The Mrp4
gene contains 31 exons, with exon 27 targeted for disruption. This region lies between
the Walker A and B motifs and is essential for their communication as well as the
facilitation of ATP hydrolysis. Disruption of the Mrp4 gene in embryonic stem cells was
achieved by replacing exon 27 with a neomycin resistance cassette by homologous
recombination. Disruption of Mrp4 expression was ensured by the use of an
oligonucleotide primer containing three in-frame stop codons engineered into exon 27.
The result was a complete loss of Mrp4 expression and function. Examination of these
animals showed breeding of Mrp4 heterozygous mice produced a normal Mendelian
ratio, indicating Mrp4 was not required for normal development. Mrp4 KO mice bred
normally with normal litter size and the expected male-female ratio. No abnormalities
were observed in the brain, liver, lung or kidney when examined by microscopic
histology. Liver and renal functions were also within the normal limits [38]. As the KO
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TMD

NBD
Figure 1-1. Structure of Mrp4. Mrp4 exhibits the classical ABC transporter core
structure with two transmembrane domains (TMD), the site of substrate binding, and two
nucleotide binding domains (NBD), the site for ATP binding. Each TMD contains six Dhelices. Both the N-terminal and C-terminal regions of the transporter are located in the
cytoplasm. Reprinted by permission from Macmillan Publishers Ltd: Gottesman MM,
Fojo T and Bates SE. Nature Reviews Cancer. 2002 Jan;2(1): 48-58.
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mouse exhibited no overt detrimental effects from the absence of Mrp4, this indicated
this mouse could be used as a crucial tool in deciphering the physiological role of Mrp4.
Understanding the pharmacological role of Mrp4 through the KO mouse model
Through this mouse model, Mrp4 was shown to play a critical protective role in
organs including the brain, liver, kidney and bone marrow cells. While Mrp4 is mainly
expressed in the luminal membrane of capillary endothelium, it has been detected in both
the basolateral membrane of choroid plexus as well as in astrocytes [38, 42]. Studies on
brain penetration revealed brain and cerebrospinal concentrations of topotecan were
higher in the KO mouse compared to the WT [38]. These animals also exhibited
increased adefovir concentrations in the brain, indicating Mrp4 is a component of the
blood-brain barrier that exports nucleoside based analogues [43]. Localized to the apical
membrane in kidney proximal tubules, Mrp4 is an important transporter for the
elimination of many substrates. The KO mouse has shown Mrp4 to be involved in the
tubular secretion of diuretics, antiviral drugs and cephalosporins [35, 37, 44]. Mrp4
protects the liver from toxic bile acid accumulation by facilitating their efflux into the
blood for renal excretion as illustrated by the sensitization of KO mice to cholestaticinduced liver injury [22]. Expression of Mrp4 in bone marrow cell lineages (e.g.
monocyte/macrophage and erythroid precursors) demonstrated its protective role against
thiopurine-induced hematopoietic toxicity as KO mice were susceptible to dose
dependent toxicity caused by the accumulation of 6-thioguanine nucleotides in these cells
[45]. These and other studies illustrate the important role the Mrp4 KO mouse has played
in understanding the critical physiological role of this transporter.
The relationship between Mrp4 and cAMP
One of the most physiologically important substrates transported by Mrp4 is
cyclic adenosine 3,5-monophosphate (cAMP). First characterized in 1957 by Sutherland
and Rall [46], this second messenger is a critical regulator of intracellular signal
transduction. It was not until the mid-1990’s, however, that the essential elements of
cAMP mediated signaling had been detailed. Upon the formation of the hormonereceptor complex, there is a conformational change of the G-protein coupled receptor.
This activates adenylyl cyclase which generates cAMP from ATP. In turn, cAMP
activates PKA which elicits a host of metabolic or physiological responses through its
downstream target phosphorylation [47].
Several transporters have been reported to efflux cAMP, but work performed in
2001 by Chen and colleges showed MRP4 transported cAMP at a higher affinity than
other previously reported transporters [39]. Cyclic AMP was originally selected as a
potential MRP4 substrate based on its structural similarity to the antiviral nucleotide
substrates as well as the similar protein topology to MRP5 which had previously been
shown to efflux cAMP [48]. Later studies highlighted the biological importance of
MRP4-mediated cAMP export. Experiments performed in the gut epithelial cell line

5

HT29-CL19A, which express both MRP4 and cystic fibrosis transmembrane receptor
(CFTR) on the apical plasma membrane and can transport cAMP across this membrane.
As CFTR is a channel activated by cAMP, inhibition of MRP4 by MK571 resulted in
increased intracellular cAMP concentrations and activation of the CFTR channel [41].
Similarly, inhibition of MRP4 in mouse ventricular monocytes resulted in increased
cAMP accumulation and stimulated contraction of the E-1 adrenocepter [49]. These
studies, along with others, illustrated how impaired MRP4 function regulates cAMP
concentration and therefore results in alterations of other cellular processes.
The relationship between Mrp4 and steroids
In addition to the other critical endogenous substrates of MRP4 established by
Chen, et al, this group was also the first to report MRP4’s ability to efflux steroid
conjugates. ABCC1, ABCC2 and ABCC3 had been previously established to transport
E217EG, a steroid derivative [50-52]. Using inside-out membrane vesicles generated
from MRP4 overexpressing insect cells, it was shown E217EG was transported by MRP4
with affinity similar to ABCC3 [52]. Further evidence of MRP4’s ability to transport
steroids came in 2003 when it was shown dehydroepiandrosterone sulfate (DHEAS)
could be effluxed by MRP4 in an inside-out membrane vesicle system [53]. As DHEAS
is a major circulating steroid in humans, mainly produced in the adrenal glands, and was
the highest affinity substrate for MRP4 at that time, these results suggested a major
function of MRP4 may be the transport of DHEAS itself or of other structurally related
steroids.
While initial data did suggest MRP4 may be responsible for effluxing steroid and
steroid-like compounds, a later study revealed neither the primary male sex hormone
testosterone nor dihydrotestosterone (DHT), the more potent reduced form of
testosterone, were transported by MRP4 [54]. Interestingly, two separate reports showed
MRP4 expression is androgen responsive as its expression is increased upon treatment
with DHT [54, 55] but is decreased upon androgen withdrawal [54]. While not a direct
transporter of testosterone or DHT, these data suggest that MRP4, as an androgen
regulated gene, may be important in the progression of androgen dependent cancers, such
as prostate cancer where MRP4 is highly expressed [54].
Leydig Cells and Testosterone Regulation
Testes and its primary cell types
The testes are the male sex organ responsible for two basic functions: sperm
production and testosterone biosynthesis. The adult testes contain several major cell
types. First, spermatogonial stem cells, residing at the luminal side of the basal
membrane of the seminiferous tubules, undergo several successive mitotic divisions,
developing into mature sperm cells. Sertoli cells, the second essential testicular cell type,
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act as a supporting structure for developing sperm as they are attached to the basal lamina
of the seminiferous tubules. Their direct contact with proliferating and differentiating
germ cells within the tubules are essential for providing both physical and nutritional
support for spermatogenesis [56]. Finally, Leydig cells lie in the interstitial space
between the seminiferous tubules and function to both synthesize and secrete testosterone
[57] (Figure 1-2). Comprising only 5% of mature testes volume, there are approximately
500 million Leydig cells present in the adult human male [58]. As adult Leydig cells are
post-mitotic, this population arises during puberty and persists for the whole adult life
[59]. A normal adult human male produces approximately 7 mg testosterone daily but
also produces other androgens such as androstenedione and dehydroepiandrosterone
(DHEA) [60]. However, due to strain differences in mice, absolute testosterone
concentrations cannot be established for this species.
Testosterone biosynthesis in the Leydig cells
Testosterone biosynthesis is stimulated when luteinizing hormone (LH) is
released form the anterior pituitary gland and acts on its receptor located on the plasma
membrane of Leydig cells. This initiates a cascade of events including the activation of
adenylyl cyclase, increased intracellular cAMP formation which then activates protein
kinase A (PKA). PKA phosphorylates the steroidogenic acute regulatory protein (StAR),
a mitochondrial associated protein, which translocates cytoplasmic cholesterol from the
outer mitochondrial membrane to the inner mitochondrial membrane. This is considered
to be the rate-limiting step in testosterone biosynthesis. In addition to StAR, cholesterol
is also brought into the mitochondria by a second importer, peripheral benzodiazepine
receptor (PBR). Once inside the mitochondria, cholesterol is converted to pregnenolone
by the enzyme cholesterol side chain cleavage (Cyp11D1) where it is then translocated
into the smooth endoplasmic reticulum. It is then converted to testosterone via a series of
reactions involving 3-beta-hydroxysteroid dehydrogenase (3EHSD), steroid 17-alphamonooxygenase (Cyp17D and 17-beta-hydroxysteroid dehydrogenase (17EHSD) [6163] (Figure 1-3). After synthesis is complete, testosterone exits the Leydig cells be a
process generally accepted as passive diffusion [64] where upon release, it enters the
circulation where it inhibits the release of LH from the anterior pituitary [65], ultimately
creating a pulsatile cycle of testosterone formation and secretion. After the onset of
puberty, over 95% of circulating testosterone is derived from the testes with the
remainder arising from testosterone precursors DHEA and androstenedione, both
originating from the adrenal gland [66].
Testosterone maintains testicular homeostasis
In the male, testosterone plays the lead role in both morphological development as
well as reproductive function. The absolute requirement for testosterone is supported by
experiments such as testosterone suppression, hormone withdrawal, and animal KO
models. Utilizing a testosterone deficiency model in rats, administration of a chronic,
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Figure 1-2. Histology of the testes. Testes histology as visualized by H&E staining
at 40X magnification. Labeled are the Leydig cells which lie in the interstitium
between the seminiferous tubules. Inside the seminiferous tubules, both the Sertoli
cells as well as developing sperm cells (spermatogonium, spermatocytes and
spermatids) are visible. Reprinted with permission from DeltaBase histology atlas.
http://www.deltagen.com/target/histologyatlas/atlas_files/male_rep/testis_40X.jpg.
Accessed October 16, 2012.
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Figure 1-3. Testosterone biosynthesis pathway. Illustration of the molecular
events involved in testosterone production by Leydig cells. Luteinizing hormone binds
to receptors on the Leydig cell plasma membrane, thereby initiating a cascade of events
that includes increased intracellular cAMP formation, translocation of cholesterol into
the mitochondria (with the involvement of steroidogenic acute regulatory protein and
peripheral benzodiazepine receptor), association of cholesterol with Cyp11D1,
production of pregnenolone from cholesterol in the mitochondria, translocation of
pregnenolone from the mitochondria to the smooth endoplasmic reticulum, and
conversion of pregnenolone to testosterone via a series of reactions in the smooth
endoplasmic reticulum. All biosynthesis enzymes are colored red.
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low dose testosterone/estradiol implant resulted in the suppression of LH to undetectable
levels with testicular testosterone concentration reported as less than 3% of controls. As
a result, production of elongated spermatids, a late stage germ cell, ceased.
Administration of high dose testosterone produced an increase in testosterone
concentration as well as normalized spermatid maturation [67]. Suppression of
gonadotropin-releasing hormone, the upstream hormone responsible for the release of LH
from the anterior pituitary, resulted in an LH deficiency and decreased intratesticular
testosterone levels, thereby creating a severe spermatogenic impairment [68]. Reduction
in testicular and prostatic weights was also observed, highlighting the importance of
testosterone in the maintenance of androgen dependent organs.
Hormone withdrawal experiments also emphasize the critical role of testosterone
in supporting spermatogenesis. Removal of androgens from adult rats by
hypophysectomy resulted in an acute, stage specific regression of the seminiferous tubule
epithelium, leading to a reduced number of early stage spermatocytes attached to the
basal lamina. Additionally, elongated spermatids exhibited an abnormal morphology
with atypical head shapes and abnormalities in the flagellum [69]. Following
hypophysectomy and elimination of all residual testosterone by flutamide,
spermatogenesis was observed to rarely proceed beyond meiosis. A minimal amount of
round spermatids could be observed and elongated spermatids were virtually non-existent
[70].
The utilization of animal KO models also enforced testosterone as an important
regulator of spermatogenesis and reproductive function. Similar to observations made
with gonadotropin suppression, the loss of the gonadotropin-releasing hormone gene in a
mouse model produced a congenital functional gonadotropin deficiency, resulting in
deficient LH and testosterone concentrations secondary to the absence of gonadotropinreleasing hormone [71]. Studies in hypogonadal mice lacking gonadotropin releasing
hormone show a decrease in testosterone synthesis genes Cyp11D1 and Cyp17D1 early as
postnatal day 5 [72], contributing to decreased testosterone and spermatogenic arrest.
Subdermal implants of either testosterone or DHT into gonadotropin-releasing hormone
deficient mice induced complete spermatogenesis and a dose-dependent increase in all
germ cell types induced by both testosterone and DHT [73]. Targeted disruption of the
Lhr gene in mice produced infertile males with reduced testicular weight, disorganized
seminiferous tubule structure and arrested spermatogenesis. Few Leydig cells were
detected, consistent with decreased testosterone concentration. Testosterone replacement
therapy in Lhr KO mice improved spermatogenic capacity and although sperm counts
remained low, sperm motility was achieved [74].
Testosterone is a critical regulator of multiple physiological processes
In addition to sustaining testicular homeostasis, testosterone is vital to multiple
physiological processes. Testosterone and DHT both act on the androgen receptor (AR)
which, when bound to an androgen, interacts with androgen response elements in the
DNA and induces subsequent effects on transcriptional activity. As multiple cell types
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express AR, testosterone can influence a vast array of actions. One major target of
testosterone is the skeletal system, with much focus on bone growth and health.
Androgen receptors are present in all layers of the human growth plate, and multiple
studies have suggested testosterone, via the AR, influences longitudinal bone growth in
early puberty [75]. In a rodent model, testosterone injected directly into the growth plate
increased its width by approximately 15% over controls [76]. Testosterone, both directly
and through aromatization to estrogen, influence bone marrow stromal cells, preadipocytes, endothelial cells within bone marrow and osteoblastic progenitors which
expresses AR and estrogen receptors [77]. In particular, DHT directly stimulates the
proliferation of osteoblast precursors and the differentiation of osteoblasts via Wnt
signaling [78].
The utilization of testosterone therapies draws attention to its ability to promote
retention and gain of muscle mass, particularly in symptomatic hypogonadal men or in
the elderly male population. Short term testosterone therapy administered to elderly men
possessing serum testosterone concentration at the lower limit of the normal range
provided benefits such as increases in serum testosterone and lean body mass as well as
decreased urinary hydroxyproline excretion, an indication of declining bone resorption
[79]. Studies examining elderly, hypogonadal men undergoing testosterone therapy have
reported increased muscle volume as well as increased leg and arm muscle strength [80],
decreased body fat coupled with increased lean body mass [81] and elevated muscle
protein synthesis [82].
Multiple epidemiological studies have stressed the importance of testosterone in
the metabolic syndrome, a term encompassing such physiological features as abdominal
obesity, insulin resistance, hypertension and dyslipidemia [83]. Testosterone
administration in non-obese men showed correlation between increased serum
testosterone and decreased visceral fat accumulation [84] while androgen therapy in older
men also resulted in reduced abdominal and peripheral adipose tissue [85]. The Telecom
Study, a large epidemiological study of healthy males, observed a potential association of
testosterone and cardiovascular risk factors. Serum triglycerides, total cholesterol, lowdensity lipoprotein cholesterol, and plasma insulin were higher while values of serum
high-density lipoprotein cholesterol were lower in men with lower serum testosterone
levels [86]. An inverse association between low endogenous testosterone levels and
increased systolic blood pressure was reported in a study analyzing normal males [87]
while middle-aged men with abdominal obesity, upon administration of a regimen of
testosterone therapy, exhibited decreased diastolic blood pressure as well as depressed
plasma triglycerides, cholesterol and fasting blood glucose concentrations [88].
While these types of studies do not mechanistically determine how testosterone
affects these processes, they do provide solid evidence of its role in the regulation of
certain human physiological conditions. As maintaining proper testosterone
concentration is a crucial, it also becomes necessary to understand the factors which
contribute to and affect normal testosterone biosynthesis itself.
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Regulation of Testosterone Biosynthesis
Functional StAR and Pbr are necessary for testosterone synthesis
The entry of cholesterol, the precursor of testosterone, into the mitochondria is
widely considered to be the rate-limiting step of testosterone biosynthesis. As a result,
proper functioning of StAR and Pbr, the two cholesterol import genes, becomes a critical
regulatory point in testosterone biosynthesis. Regulation of StAR has been demonstrated
to involve multiple transcription factors and signaling pathways. StAR was originally
identified as a phosphoprotein with phosphorylation sites for both PKA and protein
kinase C. Comparison of StAR protein sequences from multiple species indicated two
consensus PKA motifs at serine 57 and serine 195 [89] while studies performed in
glomerula cells demonstrated protein kinase C can also phosphorylate StAR [90].
Phosphorylation of StAR is crucial for proper steroidogenesis. The functional
significance of this was exhibited in a series of experiments in which serine to alanine
mutants of the StAR protein were examined in Cos-1 cells engineered to produce
steroids. Mutation at the conserved PKA target site at serine 57 had no effect on
synthesis; however, a mutation at serine 195 resulted in an approximate 50% reduction in
steroid concentration. Furthermore, mutation of this residue to an aspartic acid slightly
increased StAR activity, as measured by pregnenolone synthesis. These results suggested
that phosphorylation of StAR at serine 195 increases its biological activity which
partially accounts for the immediate effects of cAMP on steroid production [89]. Several
theories exist as to how phosphorylation by PKA affects the mechanistic function of
StAR. A report by Baker, et al showed cholesterol binding to StAR was not affected by a
mutation at serine 195 but concluded the action of PKA enhanced the capacity of StAR to
function at the mitochondria [91]. These same studies showed a reduced ability to induce
steroidogenesis when recombinant human StAR bearing the same mutation was
introduced in vitro into isolated mitochondria. Another hypothesis contends PKA
phosphorylation of StAR increases the time it spends at the outer mitochondrial
membrane, suggesting that its activity is proportional to the amount of time it resides at
the membrane [92]. The absence of StAR as examined by a KO mouse model revealed
animals that possessed a residual capacity for steroidogenesis with severely depressed
serum testosterone levels. Additionally, an accumulation of lipid droplets was observed
in both the gonads and adrenal glands of StAR KO animals [44]. As the mutation at
serine 195 is one of the many point mutations in human StAR that reportedly gives rise to
congenital lipoid adrenal hyperplasia [93], proper function of StAR is required for normal
steroidogenesis and maintenance of steroid-related functions.
As exhibited with StAR, it is crucial for Pbr, the second cholesterol importer, to
be fully functional. Whereas StAR acts to bring cholesterol into the outer mitochondrial
membrane, Pbr has been shown to translocate cholesterol from the outer mitochondrial
membrane to the inner mitochondrial membrane [94]. The critical role of Pbr was
demonstrated in studies where knocking down Pbr expression led to an attenuation of
human chorionic gonadotropin (hCG)-induced cholesterol into the mitochondria as well
as impaired steroid synthesis. This occurred even in the presence of hormone induced

12

StAR activity [95]. The disruption of Pbr in a steroid producing R2C rat Leydig cell line
resulted in a 10% production of steroids when compared to the normal cells. Addition of
a CYP11D1 substrate, 22R-hydroxycholesterol, to the Pbr negative cells restored steroid
production, indicating the cholesterol transport mechanism was impaired due to the
absence of Pbr [96]. The efforts to generate a Pbr KO mouse resulted in embryonic
lethality, suggesting Pbr is involved in the basic functions necessary for embryonic
development [97]. A conditional Pbr KO animal has not been reported so in the in vivo
contribution of Pbr has yet to be fully elucidated.
A 2001 report by West and colleagues proposed a physical interaction occurred
between StAR and Pbr as measured by fluorescence energy transfer [98]. Two
subsequent experiments suggested Pbr may actually regulate the function of StAR by
controlling its import into the mitochondria. First, in Leydig cells where Pbr levels were
knocked down, low levels of mature StAR protein formed in response to hormone
induction. This correlated with the absence of steroid formation [95]. In the same report,
it was demonstrated that a Pbr antagonist given in the presence of hCG produced an
inhibition of steroid synthesis in Leydig cells, corresponding with a decrease in mature
StAR protein formation. These results raised the hypothesis that the import and
processing of StAR into the mitochondria may be dependent on Pbr. This was tested by
the addition of in vitro transcribed/translated mature StAR into mitochondria of MA-10
Leydig cells increased steroid formation, but cells with knocked down Pbr failed to form
steroids even in the presence of StAR. Reincorporation of Pbr rescued the ability of the
mitochondria to respond to StAR, suggesting a functional interaction between StAR and
Pbr at the outer mitochondrial membrane where Pbr controls StAR import and processing
into mitochondria as well as StAR mediated cholesterol transport [95]. These data
demonstrate the importance of both StAR and Pbr as critical regulators of steroidogenesis
and also highlight their dependence on each of for maximal functional capacity.
Cyclic AMP regulates multiple processes in the testosterone synthesis pathway
The second messenger, cAMP, is responsible for the regulation of a host of
biological processes, often through the activation of PKA. Careful scrutiny of the
testosterone biosynthesis pathway reveals multiple steps are under cAMP regulation. The
initial step, activation of Lhr, is regulated by cAMP concentration. Experiments
performed by Kishi, et al in LH/hCG receptor (alternate name for Lhr) expressing rat
granulosa cells indicated basal cAMP activity is required for LH/hCG receptor
expression. However, when cells were incubated for longer periods of time with hCG,
the LH/hCG receptor exhibited decreased mRNA expression. The authors concluded that
a labile destabilizing factor induced by cAMP may be responsible for the degradation of
the LH/hCG receptor mRNA [99]. Studies performed several years earlier in MA-10
cells showed that when treated with hCG or a cAMP derivative, 8-bromo-cAMP, there
was a reduction in LH/hCG receptor mRNA expression and, additionally, a decrease in
receptor number on the membranes as a result of receptor mediated endocytosis [100].
The reduction in LH/hCG receptor mRNA expression was shown to be a result of a
decreased rate of transcription when these cells were treated with 8-bromo-cAMP [101].
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The decrease in receptor expression as a result of increased cAMP is a regulatory
checkpoint to prevent continuous receptor activation and therefore constant stimulation of
steroid synthesis.
Cholesterol import genes are also subject to cAMP regulation. Cyclic AMP
activates transcription of cAMP-responsive genes through the interaction of the cAMP
response element (CRE) binding protein (CREB) with a conserved CRE sequence in the
promoter regions of these genes [102]. Instead of the typical CRE binding motif, StAR
contains a cAMP responsive region which is mediated by protein kinases [103]. The
classical cAMP-PKA signaling cascade has been shown to upregulate the transcription of
the StAR gene [104, 105]. Studies performed by Stocco and colleagues reported
transfection of MA-10 and Cos-1 cells with a vector containing wild-type CREB resulted
in increased steroidogenesis, StAR promoter activity and StAR mRNA expression. The
increase in activity was not observed when a dominant negative or non-phosphorylatable
CREB was transfected into cells [106]. It was concluded that while the StAR promoter
did not contain a consensus CRE site, CREB could play a role in StAR promoter
transactivation, potentially by binding to an alternate non-consensus site or by binding to
the promoter in an indirect manner. Cyclic AMP has been shown to regulate StAR
protein expression through PKA activity. Mouse adrenocortical Y1 cells and derived
PKA mutant adrenal tumor Kin-8 cells were treated with 8-bromo-cAMP, with StAR
mRNA detectable in both cell lines, but Kin-8 cells had only a 50% expression level
compared to that of the Y1 cells. Increased StAR protein was observed in the normal Y1
cells while it was undetectable in the mutant PKA Kin-8 line [107]. Analysis of the
second cholesterol importer, Pbr, has not revealed it to be a target of CREB activation but
a study has suggested there is a cAMP-inducible element regulating its structure and
function. Using MA-10 cells as a model system, Boujrad and others showed treatment
with hCG resulted in increased cAMP concentration as well as elevated steroid formation
as a result of hCG binding to benzodiazepine. This was completely reversed upon the
addition of a selective PKA inhibitor, indicating Pbr is potentially regulated by cAMP
[108].
Phosphorylation of CREB by PKA is also a critical cAMP-regulated component
of the testosterone biosynthesis pathway. Three genes directly involved in the synthesis
of testosterone, Cyp17D, Cyp11D and 3EHSD, all contain CREB binding sites within
their promoters [109]. This effect can be observed by studies which demonstrated that, in
the absence of cAMP, de novo synthesis of Cyp17D was halted in cultured Leydig cells,
and the major steroid product produced was progesterone. Upon chronic cAMP
treatment, the major product was shifted back to testosterone, indicating the requirement
of cAMP for Cyp17D function and, thereby, its importance in sustaining testosterone
synthesis [110]. The duration of phosphorylation at serine 133, the CREB
phosphorylation site, can determine the efficacy of downstream target gene expression.
Experimental analysis has shown sustained phosphorylation promotes increased CREB
target gene induction while a rapid phosphorylation/dephosphorylation cyclic did not
promote gene induction [111].
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Testosterone metabolism
Steroid hormones are maintained by a dynamic balance between steroidogenesis
and steroid inactivation (Figure 1-4). This ensures correct physiological function is
continuously occurring. While the liver is the most important organ involved in steroid
hormone metabolism, other organs including the skin [112], lung, spleen and intestine
[113] have been implicated in the breakdown of steroids. Steroid metabolism does not
always reduce the biological activities of hormones but instead can render them inactive
through metabolic conversion. Elimination of these lipophilic molecules from the cell
occurs through an array of enzymatic reactions followed by their transport across the cell
membrane. In general, the major metabolic pathways of steroids in humans are the
following: oxidation, primarily through hydroxylation, by cytochrome P450 (CYP450)
enzymes [114], conjugation with glucuronide [115] or sulfate [116] and O-methylation
by catechol O-methyltransferase [117]. Steroid hydroxylation produces products with
higher polarity so the metabolites are more easily conjugated and excreted [118]. As
with most steroid metabolism, the liver is responsible for the majority of steroid
metabolism resulting from CYP450 hydroxylation [114]. In humans, there are 18
families and 43 subfamilies of CYP450 genes [119]. Steroids are metabolized by several
members of the CYP450 families including CYP1A, CYP1B, CYP2B, CYP2C,
CYP3A,CYP7A and CYP7B [113] however CYP2B and CYP3A are largely responsible
for testosterone metabolism. Hydroxylation of testosterone can occur at, but is not
limited to, the following positions: 2D, 6D, 6E, 7D,16D, 16E, and 17E>@The
CYP3A family isoforms account for up to 60% of the total CYPs present in the human
liver with CYP3A4 considered to be the most versatile enzyme involved in the
metabolism of endogenous steroid hormones [121]. Studies have demonstrated CYP3A4
is responsible for testosterone 11E-, 15E-, and 16E-hydroxylation [122]. The second
important CYP family involved in testosterone metabolism, CYP2, accounts for
approximately 30% of human hepatic CYPs [123]. It has been shown that human
CYP2B6 is the only CYP involved in 16D- [124] and 16E-hydroxylation [125].
CYP2C19 is also capable of metabolizing testosterone, forming androstenedione as a
major metabolite [126]. CYP19A1, also known as aromatase, can transform testosterone
into estradiol in regions such as the ovary, placenta and brain [127].
As it has been shown CYPs metabolize steroids, there are also reports that
steroids are able to regulate CYP expression, namely mouse Cyp2b10 (CYP2B6 in
humans) and testosterone. Work performed in mice by Honkakoski, et al demonstrated
that castrated males presented with elevated Cyp2b10 mRNA and protein expression in
comparison to intact animals. This was accompanied by an increase in Cyp2b10 catalytic
activity. This was alleviated upon testosterone administration to the castrated males
[128]. These data were one of the first to suggest a negative correlation between
Cyp2b10 expression and testosterone concentration. Later evidence further confirmed
this result. As hepatic Cyp2b10 had been identified as a direct target of the nuclear
orphan receptor CAR [129], experiments were performed in which HepG2 cells were
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Figure 1-4. The balance between steroid biosynthesis and inactivation. Steroid
hormones are maintained through a dynamic balance between steroidogenesis and
steroid inactivation to ensure their proper physiological functions, which are largely
mediated through the activation of ligand-specific steroid hormone receptors.
Reprinted from Chemico-Biological Interactions, 147(3), You L, Steroid hormone
biotransformation and xenobiotic induction of hepatic steroid metabolizing enzymes,
233-246, copyright 2004, with permission from Elsevier.
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transfected with NR1, a CAR-responsive enhancer found in both mouse and human
Cyp2b genes. Treatment with either testosterone, androstenedione, progesterone or
androstenediol all resulted in a dose-dependent decrease in NR1 activity, indicating
repression occurred through CAR activation. This was reversed by the addition of
estrogens [130]. These collective results indicate Cyp2b10 and testosterone exist in a
crucially balanced relationship, as the expression of one component tightly regulates the
expression of the other.
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CHAPTER 2. THE ABSENCE OF MRP4 IN LEYDIG CELLS RESULTS IN
REDUCED INTRATESTICULAR TESTOSTERONE CONCENTRATION*
Introduction
Expression of multiple ABC transporters present in the testes has been well
established in the literature. Pgp, Abcg2, Abcc1, Abcb9, Abcb6, Abcb8 and Abca5 have
all been identified in various testicular cells types. Abca5 localization is reported in
Leydig cells [131]; however, its exact role has yet to be elucidated. Similarly, the precise
contribution of Abca9, Abcb6 and Abcb8 has not been determined with respect to
testicular function. Interestingly, the transcripts of each of these transporters have been
identified in distinct cell types. Abcb9 was identified in Sertoli cells while Abcb6 was
expressed in the germline, with positive expression observed in spermatocytes and early
spermatids. Abcb8 transcript was detected in Sertoli cells and peritubular cells as well as
spermatogonia and spermatocytes [132]. Even without full functional characterization, it
is immediately detectable that ABC transporters have no discernible distribution pattern
in the testes.
Other ABC transporters have been more extensively characterized with respect to
functional contribution as well as cellular localization. Immunohistochemical staining
has revealed that Pgp, Abcg2 and Abcc1, like the aforementioned transporters, have no
distinct expression pattern in the testes. Pgp is found in myoid cells, Leydig cells and
endothelial cells; Abcg2 has been identified in myoid and endothelial cells while Abcc1
is localized to both Sertoli cells, and to a lesser extent, Leydig cells [133]. Additionally,
Abcg2 was recently discovered to be localized to spermatogonial stem cells, providing
the first evidence of this transporter in this compartment [134]. As these transporters are
located in different cell layers of the normal testes, it was suggested they provided
optimal protection of spermatogenesis by exporting potentially harmful substrates. While
there are multiple studies confirming the protective role of these transporters in the testes,
that data will not be discussed as our main focus concerns the relatively undefined role of
transporters in regulating testicular steroid biosynthesis.
A 2010 report by Sivils, et al was the first to describe how the absence of an Mrp
transporter, namely Abcc1, resulted in reduced serum and testicular testosterone levels in
the absence of drug challenge [135]. This work provided the first evidence that a
transporter may influence the steroid biosynthetic process although the mechanism was
not elucidated.
Prior to the work presented here, it was well established that Mrp4 is expressed in
both human and murine testes [136, 137], although its cellular localization and precise
contribution had yet to be established. As it might be hypothesized that Mrp4 plays a
* Modified with permission. Morgan JA., et al. Deregulated hepatic metabolism
exacerbates impaired testosterone production in Mrp4-deficient mice. J Biol Chem,
2012. 287(18): p. 14456-66 [138].
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protective role in the testes, as seen with Pgp, Abcg2, and Abcc1, no data existed to
support this. There was also no evidence linking Mrp4 as a regulator of testosterone
biosynthesis although it was reported that neither testosterone nor DHT were substrates
for Mrp4 [54]. Through the use of the Mrp4 KO mouse, my contribution was to provide
a more in-depth understanding of the importance Mrp4 provides in testes, beginning with
its cellular localization and examination of testicular function.
Experimental Procedure
Animals
The generation of the Mrp4 KO mouse had been described previously [38]. All
mice used during the duration of these studies were maintained on a mixed C57BL6/129
background and generated by intercrossing littermates. Mice were housed and fed under
identical conditions until experiments were performed.
Immunohistochemistry (IHC)
Whole testes were harvested from Mrp4 WT and KO mice and immediately
formalin fixed. Samples were submitted to the St. Jude Veterinary Pathology Core where
they were paraffin embedded and sectioned into 4 micron sections. Following standard
slide mounting procedure, the testes sections were stained with M4I-10, a monoclonal
Mrp4 antibody (a gift from Dr. George Scheffer). Testes were stained with hematoxylin
& eosin (H&E) for analysis of overall testicular morphology. Additionally, they were
stained with an antibody for the cell proliferation marker, Ki67, and for terminal
deoxynucleotidyl tranferase dUTP nick end labeling (TUNEL), an antibody detecting cell
apoptosis. All staining was performed using the LabVision 720 autostainer (Thermo
Shandon).
Immunoblotting
Testes from pre-pubertal and adult WT and KO mice were ultrasonically
disrupted in a mixture of M-Per reagent (Thermo Scientific) plus a protease inhibitor
cocktail (Roche Diagnostics). Protein concentration was determined by the Bradford
assay method [139]. Proteins were suspended in a mixture of 2X Laemmeli sample
buffer containing 5% E-mercaptoethanol but were not denatured by boiling. Proteins
were then size fractionated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis. All gels were hand cast. The running gel was composed of 29.2%
acrylamide-0.8% Bis (National Diagnostics, Inc.), 1.5 M Tris-0.4% SDS (Sigma
Aldrich), double deionized water, 10% ammonium persulfate (Biorad) and Temed
(Biorad). The stacking gel consisted of 29.2% acrylamide-0.8% Bis (National
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Diagnostics, Inc.), 0.5 M Tris-0.4% SDS (Sigma Aldrich), double deionized water, 10%
ammonium sulfate (Biorad) and Temed (Biorad).
Following size fractionation, the proteins were transferred onto a nitrocellulose
membrane (Midwest Scientific) overnight in a solution of 10% 1X Tris-glycine
(Amresco), 20% methanol, and 70% double deionized water. Following transfer, blots
were blocked in a 10% milk/phosphate buffered saline (PBS)-Tween solution for 60
minutes then washed 3X for 5 minutes with 1X PBS-Tween. Primary antibodies were
made in a 10% milk/PBS-Tween solution, and blots were rocked at room temperature for
150 minutes then washed 5X for 5 minutes each in 1X PBS-Tween. Secondary antibody
were made in the same solution and incubated for 60 minutes at room temperature,
followed by the same washing step as just described. Blots were then exposed to
enhanced chemiluminescence reagent (GE Healthcare) for one minute and protein was
visually detected by exposure to film (Denville Scientific).
Testicular testosterone measurement
Testicular testosterone concentration was measured from WT and KO mice by
harvesting testes, homogenizing in 1X PBS with a glass Dounce homogenizer, and
centrifuging at 5900 x g for 5 minutes at 4oC. The supernatant was then combined with 1
ml diethyl ether, vortexed, and the organic phase was collected and dried down under a
stream of N2 at room temperature. The dried fraction was reconstituted in 0.2 ml 1X
PBS. Testosterone concentration was then measured by a 125I-labeled radioimmunoassay
(RIA) (MP Biomedicals) according to the manufacturer’s instructions. Concentration of
testicular testosterone was expressed as ng/mg of testes weight.
Immunohistochemical counting
All IHC quantitation was performed on a minimum of three mice per age and
genotype group. Counts were taken on five random fields per slide at 40 X magnification
on a Nikon Eclipse Ti microscope. For TUNEL and Ki67 staining, the cell was
considered positive if greater than 50% of the individual cell was stained.
Results
Mrp4 is localized to Leydig cells
As expected, immunoblot analysis revealed Mrp4 protein expression in whole
testes extract from Mrp4 WT testes. Mrp4 was also detected in the isolated Leydig cell
fraction from WT testes. No protein expression was observed in Leydig cells or whole
testes from KO animals. Analysis of Abcc1 (Mrp1) showed decreased expression in
Leydig cells as compared to whole testes, where Abcc1 (Mrp1) is highly expressed in the
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Sertoli cells that reside in the seminiferous tubules [140] (Figure 2-1A). In accordance
with the immunoblot analysis, IHC confirmed Mrp4 localization in the Leydig cells of
both mouse (Figure 2-1B) and human (Figure 2-1C). Mrp4 was undetectable inside the
seminiferous tubules, indicating it is not expressed in Sertoli or germ cells. These results
provide the first evidence of Leydig cell localization of Mrp4.
The absence of Mrp4 in Leydig cells does not affect general reproductive
parameters
Phenotypically, Mrp4 WT and KO animals are indistinguishable from one
another. Both genotypes of mice are reproductively normal, producing comparable litter
sizes (Figure 2-2A) and ratios of offspring that conform to classical Mendelian
inheritance (not shown). In addition, testes weight was comparable between the
genotypes, although KO mice did exhibit a slight increase (Figure 2-2B). As general
reproductive parameters were not altered between WT and KO mice, the loss of Mrp4
was then examined with respect to total Leydig cell number. Immunohistochemical
analysis of testes of mice ranging in age from 3 weeks to 6 weeks revealed similar
number of absolute Leydig cells, with the exception of 3 week old KO mice. These mice
exhibited an approximate 30% reduction in Leydig cell number (Figure 2-2C). Leydig
cell proliferation analysis of the same samples demonstrated WT and KO mice had
proportional numbers of proliferating cells (Figure 2-2D). However, 6 week old Mrp4
KO mice did possess fewer proliferating cells than did their WT counterparts. Overall,
our results revealed the absence of Mrp4 in Leydig cells does not generally affect their
total cell number or proliferation status.
Pre-pubertal Mrp4 KO mice are deficient in testicular testosterone
It had been previously observed that the loss of an Mrp transporter expressed in
the Leydig cells resulted in testosterone deficiency [135]. In addition to Leydig cells, this
transporter was simultaneously expressed in Sertoli cells, so the transporter’s exact role
in testosterone reduction could not be discerned with respect to its Leydig cell expression.
For these studies, our initial analysis revealed Mrp4 expression to be solely localized to
the Leydig cells, making it possible to reveal the role Mrp4 plays in these cells and how
its loss affects the testes as a whole.
Initial experiments focused on pre-pubertal mice. Prior work in our lab revealed
Mrp4 protein expression increases in the testes as mice mature from pre-pubertal animals
to adulthood (Figure 2-3), so it was of interest to examine our animals at two different
stages of sexual maturity. Pre-pubertal mice were designated as exactly 21 days of age as
genes responsible for steroid biosynthesis can show upregulation as early as 25 days after
birth [141, 142], indicating the onset of puberty. Examination of testicular testosterone
concentration revealed a drastic decrease in levels of the Mrp4 KO mouse, only 20% of
the concentration observed in WT animals (Figure 2-4).
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Figure 2-1. Mrp4 is expressed in Leydig cells. (A) Immunoblot analysis of Mrp4
and Mrp1 protein in Leydig cell and testes. Immunohistochemical analysis (400x
magnification) shows Mrp4 is visible in both (B) mouse and (C) human Leydig cells as
indicated by the red staining (see arrows).
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Figure 2-2. Mrp4 KO mice display normal reproductive parameters. (A) Average
number of pups per litter in WT (n = 51 litters) and KO (n = 53 litters) matings.
(B) Mean testes weight of Mrp4 WT (n= 37) and KO (n= 37) mice. (C) Mean testicular
Leydig cell counts (n = 3 mice per age and genotype). (D) Mean testicular Leydig cell
proliferation (Ki67+ cells per total Leydig cell number) (n = 3 mice per age and
genotype). All error bars = SE.
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Figure 2-3. Mrp4 protein expression increases with age. Immunoblot analysis
of Mrp4 expression in testes of WT and KO mice (left). Actin was used as a loading
control (top). Expression ratios plotted from absolute band intensity (bottom) using
ImageJ software.
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Figure 2-4. Pre-pubertal Mrp4 KO mice are deficient in testicular testosterone.
Testosterone concentration in Mrp4 WT (n = 9) and KO (n = 4) testes as measured by
125
I-labeled radioimmunoassay.
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To assess how the absence of Mrp4 affected the testes, several parameters were
analyzed. As testosterone is required for gamete maturation [143], analysis was
conducted on whole testes in order to determine germ cell maturation status. Primary
spermatids were detected in 50% of the seminiferous tubules of WT mice compared to
only 25% in KO mice (Figure 2-5A), indicating WT testes possess a more mature germ
cell population. In conjunction, germ cell proliferation was investigated in the same
sample set. Using Ki67, a marker for cell proliferation, a 33% reduction in proliferating
germ cells was observed in the KO seminiferous tubules (Figure 2-5B). This result
suggested defective germ cell mitosis occurred in the absence of Mrp4. To further
confirm this result, expression analysis of testicular RNA showed genes important in
germ cell mitosis, including Ccnb1, Cdc25c, and E2f, were slightly reduced in KO testes.
pRm1, a gene important in gamete chromatin assembly, was drastically reduced in these
animals (data not shown) confirming germ cell maturation is defective in KO mice. In
addition, as germ cell maturation is controlled by both proliferation and apoptosis [144],
the number of apoptotic cells was assessed by TUNEL staining of the whole testes.
Results showed a greater than 30% increase in TUNEL positive cells in tubules of KO
mice as compared to their WT counterparts (Figure 2-5C).
Conclusions
We show that Mrp4 is localized specifically to the Leydig cells of the testes, but
its absence does not affect general reproductive parameters including litter size or
Mendelian inheritance ratio. Testes weight is unaltered between the genotypes, and total
Leydig cell number is comparable between WT and KO as mice approach adulthood with
the exception of the 3 week age. Similarly, Leydig cell proliferation was comparable as
mice aged.
Examination of pre-pubertal Mrp4 KO mouse testes revealed decreased
intratesticular testosterone concentration in comparison to WT animals. This was
accompanied by impaired spermatogenesis and reduced germ cell proliferation.
Additionally, increased germ cell apoptosis was observed in these same KO animals.
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Figure 2-5. Pre-pubertal Mrp4 KO mice exhibit impaired testicular morphology.
(A) Testicular morphology of WT and KO mice (H&E stain, 40x magnification).
Arrows indicate elongated spermatids in WT mice but immature spermatogonia are only
detected in KO mice. Enlarged insets show these cells in the seminiferous tubules lumen.
Graph below quantitates percentage of seminiferous tubules containing elongated
spermatids as examined in a high power field. (B) Cell proliferation in testes utilizing
Ki67 staining. Graph below is a quantification of Ki67+ cells expressed as mean number
per high power field (40x magnification). (C) Mean number of apoptotic germ cells per
high power field (40x magnification) by TUNEL assay. All error bars = SE.
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CHAPTER 3.

TESTICULAR TESOSTERONE BIOSYNTHESIS IS
IMPAIRED IN MRP4 KO MICE*
Introduction

Testosterone biosynthesis is dependent on both acute and chronic stimulation of
Leydig cells by the pituitary hormone LH which binds to specific high affinity receptors
on the cell surface. This results in the activation of adenylate cyclase followed by
increased cAMP, mediating both acute and chronic effects of LH. The rapid, acute
response involves the transport of cholesterol, the precursor of testosterone, to the inner
mitochondrial membrane by way of cholesterol transport proteins StAR and Pbr.
Chronic stimulation of Leydig cells by LH is required for optimal expression of enzymes
and proteins necessary for testosterone biosynthesis. The beginning steps of the
conversion of cholesterol to the ultimate product of testosterone begin with cholesterol
metabolized to pregnenolone through the actions of the enzyme Cyp11D. Pregnenolone
then exits the mitochondria and is transferred to the smooth endoplasmic reticulum where
addition reactions involving 3EHSD1, Cyp17D1, and 17EHSD1 result in the final product
of testosterone [61-63]
Interference with many of the steps involved in testosterone biosynthesis can
result in decreased, or in some instances, complete ablation of testosterone production.
Studies utilizing Lhr KO mice demonstrated that adult testes were devoid of mature
Leydig cells and exhibited thin seminiferous tubules with arrested spermatogenesis. Full
steroidogenesis was not achievable without gonadotropin stimulation [145, 146].
Impeded StAR function and expression also negatively impacts steroid biosynthesis.
Mutation of the conserved PKA target site serine 195 resulted in an approximate 50%
reduction in steroid production in Cos-1 cells engineered to generate steroids [89].
Decrease in StAR mRNA and protein expression by environmental factors such as
exposure to phthalate esters and heavy metals also result in decreased steroidogenesis
[147]. Similarly, loss of the second cholesterol transport protein, Pbr, produces impaired
steroid biosynthesis. Targeted disruption of Pbr in a R2C Leydig cell line resulted in
steroid production in only 10% of the cells when compared to WT [97]. These collective
results demonstrate the importance of an unimpaired biosynthesis pathway is necessary
for maximal steroid production.
In addition to the above mentioned mechanisms, these and other genes directly
involved in steroid biosynthesis are regulated by cAMP. Anakwe and Payne exhibited
that, in the absence of cAMP. de novo synthesis of Cyp17D ceases in cultured Leydig
cells, with the major steroid product becoming progesterone. Chronic cAMP treatment
then shifted the major product back to testosterone, indicating the requirement of cAMP
for Cyp17D function and synthesis [110]. Additionally, Cyp17D, Cyp11D and 3EHSD all
_______________________________________________________________________
*Modified with permission. Morgan JA., et al. Deregulated hepatic metabolism
exacerbates impaired testosterone production in Mrp4-deficient mice. J Biol Chem,
2012. 287(18): p. 14456-66 [138].
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contain promoters with CREB binding sites [109], a transcription factor whose activation
results in increased transcription of these downstream target genes. As CREB activation
is a cAMP dependent process, it is required for maximal expression of these biosynthesis
genes.
Inhibition of cAMP by a phosphodiesterases (PDE) expressed in Leydig cells also
highlighted the importance of cAMP as a modulator of testosterone biosynthesis.
Through the use of isolated Leydig cells in a PDE8A KO mouse model, an increase was
observed in LH stimulated testosterone production, likely due to increased cAMP
concentration. PDE8A KO Leydig cells treated with 3-isobutyl-1-methylxanthine
(IBMX), a pan PDE inhibitor, exhibited an even more robust increase in testosterone
concentration when stimulated with LH [148]. These results indicate inhibition of cAMP
dependent PDEs is a potent way to modulate LH signaling and steroid biosynthesis while
also emphasizing cAMP concentration is critical for testosterone production.
Based on the results obtained in Chapter 2, we sought to determine the
mechanism by which testicular testosterone concentration was reduced in Mrp4 KO mice.
As the testosterone biosynthesis pathway can be regulated at multiple levels, it was
imperative to examine each individual component to determine the exact defect that
resulted in decreased testosterone.
Experimental Procedure
LH measurement
Whole blood was collected by retro-orbital eye bleed from WT and KO mice,
incubated at 4oC for 2 hours, then centrifuged at 5900 x g for 5 minutes in order to
separate the serum from the remaining clotted blood. LH concentrations were assayed
from the serum by the Center for Research in Reproduction Ligand Assay and Analysis
Core at the University of Virginia School of Medicine (Charlottesville, VA). LH was
measured by an immunoradiometric sandwich assay and the final concentration was
expressed in ng/ml.
Immunoblot analysis
Immunoblot analysis was performed in whole testes samples as described in
Chapter 2 with the exception that all protein samples examined were denatured by boiling
for 5 minutes at 95oC in a 2X Laemmeli sample buffer containing 5% E-mercaptoethanol.
The assayed proteins were Lhr (AbD Serotec), StAR (Santa Cruz Biotechnology, Inc.),
Pbr (Everest Biotech), Cyp11D1 (Chemicon International), 3EHSD1 (Abcam), Hmgcs1
(Abcam), Dhcr7 (Santa Cruz Biotechnology, Inc.), VDAC (Mitosciences), CREB and
phospho-CREB Ser133 (Cell Signaling Technology). Relative protein quantities were
determined by densitometry using ImageJ software.
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Leydig cell testosterone measurement
Leydig cells were isolated as previously described from three mice of each
genotype. Samples were pooled for analysis, and testosterone was measured directly
using the RIA as described previously. Testosterone concentration is expressed as ng/ug
protein.
cAMP determination
Basal cAMP measurements were taken from freshly isolated Leydig cells which
were immediately lysed in 0.1 M hydrochloric acid. Intracellular cAMP content was
assayed using the acetylated version of a cAMP complete enzyme-linked immunosorbent
assay (Enzo Life Sciences ) according to the manufacturer’s instructions. Results are
expressed as pmol per 106 cells.
Under stimulated conditions, isolated Leydig cells were plated at a density of 106
cells per well in a six well plate using DMEM/F12 media (Invitrogen). Cells were treated
with a 10 mIU/ml LH (Sigma), a physiological concentration, and 0.1 mM IBMX
(Sigma), a PDE inhibitor. Following a three hour incubation at 37oC, cells were collected
using a cell lifter, centrifuged at 5900 x g for 5 minutes at 4oC, and cAMP concentration
was assayed as described above.
CREB phosphorylation
Leydig cells were isolated from WT and KO mice, plated at a density of 106 cells
in a six well plate in DMEM/F12 media (Invitrogen). Cells were then stimulated with 10
mIU/ml LH for the indicated time points. Cells were harvested, protein was measured by
Bradford assay, and the samples were subjected to immunoblot analysis probing for
phospho-CREB133 and total CREB (Cell Signaling Technology). The loading control
was an unknown protein that cross-reacted with the antibody but remained constant
among the samples. Densitometry was assessed using ImageJ software.
RNA isolation
Leydig cells were isolated from three mice of both WT and KO testes and
homogenized in 1 ml Trizol Reagent (Invitrogen) using a hand held homogenizer.
Samples were incubated at room temperature for 5 minutes to allow for complete
dissociation of nucleoprotein complexes. Following incubation, 0.2 ml chloroform was
added, samples were vigorously shaken for 15 seconds and incubated at room
temperature for 3 minutes. Samples were then centrifuged at 12000 x g for 15 minutes at
4oC. After centrifugation, the aqueous phase was collected, mixed with 0.5 ml isopropyl
alcohol and incubated at room temperature for 10 minutes. Samples were centrifuged at
12000 x g for 10 minutes at 4oC. The supernatant was removed, the pellet was washed
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with 1 ml 75% ethanol, vortexed, then centrifuged at 7500 x g for 5 minutes at 4oC. The
ethanol wash was removed, the pellet was air dried then dissolved using RNAse free
water by incubating for 10 minutes for at 60oC.
Real-time PCR
Real-time polymerase chain reaction (PCR) was performed on isolated Leydig
cells using 20 ng of diluted cDNA with SYBR Green (Invitrogen) and 300 nM gene
specific primers using the ABI 7900HT sequence detection system (ABI). Primer
sequences were designed using Primer Express (ABI). The PCR protocol was as follows:
10 minute denaturation step, 40 cycles of two-step PCR (15 seconds at 95oC and 60
seconds at 60oC) followed by a dissociation step (15 seconds at 95oC, 15 seconds at 60oC
and 15 seconds at 95oC). The fold difference in expression was normalized to the
housekeeping gene Gapdh and was calculated using the ''Ct method. The following
primer sequences were utilized: Lhr (sense, 5’-GCGCGCCGGATGGT-3’; antisense, 5’AAAGCTTGTGATGGGATTACTTTGA-3’), StAR (sense, 5’CGGGTGGATGGGTCAAGTT-3’; antisense, 5’GGACAGCTCCTGGTCACTATAGAGT-3’), Pbr (sense, 5’CTGGACACTGGCTCCCATCT-3’; antisense, 5’CCAGCTCTTTCCAGACTATGTAGGA), Cyp11D1 (sense, 5’-GGCCGGCGGATTGC3’; antisense, 5’-CATCACGGAGATTTTGAACTTCAA-3’), 3EHSD1 (sense, 5’CCCAGGCAGACCATCCTAGA-3’; antisense, 5’GAACACAGGCCTCCAATAGGTT-3’), and Cyp17D1 (sense, 5’CCAGAGAAGTGCTCGTGAAGAA-3’; antisense, 5’-CCTTTTCCTTGGTCCGACAA3’).
Microarray expression analysis
RNA was purified from Leydig cells of pre-pubertal and adult WT and KO mice.
Analysis used nine pre-pubertal and five adult mice per genotype. RNA from each age
and genotype group was combined prior to analysis. After RNA quality was confirmed
(Agilent Bioanalyzer 2100), RNA was processed using the Affymetrix one-cycle target
labeling protocol and hybridized overnight to the Affymetrix Mouse 430 vs 2 array.
Array signals were summarized using the MAS 5 algorithm and log2 transformed prior to
analysis.
Microarray analysis was performed by using the Spotfire Decision Site version
9.1 (TIBCO). For genes interrogated by multiple probe sets, a single expression value
was calculated using the maximum signal reported across redundant probe sets. Genes
associated with steroid metabolism were identified by annotations curated from Entrez
Gene, Gene Ontology and GeneGo Metacore terms [149]. For cAMP target genes, the
PKA, CREB and cAMP pathways were curated from known direct and indirect target
genes.
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Results
Expression of Lhr, but not LH concentration, is decreased in Mrp4 KO mice
Both LH concentration and the upregulation of Lhr in response to stimulation are
critical initial steps in the regulation of testosterone synthesis. Because of this, our
examination began with these critical factors. In adult mice, serum LH concentration was
not significantly different between the genotypes (Figure 3-1A). However, immunoblot
analysis of total Lhr protein revealed an approximate reduction of 70% in KO mice
(Figure 3-1B). While the comparable circulating LH levels were an unexpected result as
we would have predicted elevated concentrations in the KO due to decreased
testosterone, decreased Lhr protein expression was the first indication that a defect
existed in the biosynthesis pathway itself.
Lhr signaling is essential for steroidogenesis as well as cholesterol homeostasis
[150]. Two genes important in de novo cholesterol biosynthesis were examined in
isolated Leydig cells by real-time PCR. Both Hmgcs1 and Dhcr7 mRNA levels were
decreased in KO mice as compared to WT animals (Figure 3-2A). Measurement of total
serum cholesterol showed no difference in levels between the genotypes (Figure 3-2B),
indicating the defect in LH-regulated cholesterol biosynthesis appears to be Leydig cell
specific.
Cyclic AMP concentration is drastically diminished in Mrp4 KO Leydig cells
The concentration of cAMP within the Leydig cell is crucial for the regulation of
testosterone biosynthesis. As our results showed upstream components of the
testosterone biosynthesis pathway were downregulated, it was essential to measure
cAMP in our mice to determine how its potential alteration may contribute to decreased
testicular testosterone in Mrp4 KO mice. Prior to analysis of cAMP levels, measurement
of testosterone concentration in isolated Leydig cells revealed decreased levels in Mrp4
KO cells (Figure 3-3A), analogous to the reduction observed in whole testes sample.
These results aid in confirming the deficiency in testosterone originates in Leydig cells
and is not dependent on other factors acting on these cells.
Analysis of basal cAMP concentration in Leydig cells showed an inherent defect
in cAMP concentration (Figure 3-3B). In Leydig cells stimulated with a physiological
concentration of LH, cAMP concentration remained lower in Mrp4 KO than in WT cells
(Figure 3-3C). Although cAMP levels were elevated in both genotypes in response to
LH stimulation, KO Leydig cells exhibited a modest two fold increase in cAMP
concentration while WT cells produced a five-fold elevation over basal levels.
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Figure 3-1. Luteinizing hormone receptor expression, but not LH concentration,
is altered in Mrp4 KO mice. (A) Serum LH concentration measured by
radioimmunoassay (n = 3 mice/genotype). (B) Lhr protein in Leydig cells as assessed by
immunoblot analysis. A nonspecific band was used as a loading control. Graph below
expresses ratios of band intensity. All error bars = SE.
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Figure 3-2. Cholesterol biosynthesis genes are reduced in Mrp4 KO mice but
serum cholesterol concentrations are unchanged between genotypes.
(A) Cholesterol gene expression in KO Leydig cells by real-time PCR, presented as the
mean ratio of expression in WT cells. (B) Serum cholesterol concentration measured
by enzymatic assay (WT, n = 10, KO, n = 8). All error bars = SE.
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Figure 3-3. Cyclic AMP concentration is decreased in Mrp4 KO Leydig cells.
(A) Testosterone concentration in adult Leydig cells as measured by radioimmunoassay
(n = 3 mice/genotype). (B) cAMP concentration in Leydig cells under basal conditions
as evaluated by enzyme immunoassay (n = 3 mice/genotype). (C) cAMP concentration
in Leydig cells stimulated with 10mIU LH (n = 3 mice/genotype). All error bars = SE.
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CREB activation, a cAMP dependent phenomenon, and downstream target gene
expression are reduced in Mrp4 KO Leydig cells
To further validate the decrease seen in cAMP concentration in Mrp4 KO Leydig
cells, both CREB phosphorylation status and its downstream target gene expression were
examined. CREB mediated transcription requires phosphorylation at a particular residue,
Ser133. Activated by a variety of protein kinases, this site is phosphorylated by cAMP
dependent PKA [151] thereby promoting gene transcription of a wide array of targets.
Initial experiments focused on the phosphorylation status of CREB in WT and KO
Leydig cells. Stimulation with a physiological concentration of LH showed a rapid
increase in the amount of phospho-CREB while decreasing total CREB protein in WT
samples. In stark contrast, KO Leydig cells exhibited slow CREB phosphorylation under
LH stimulation and show minimal change in the phospho-CREB/CREB ratio versus the
unstimulated state (Figure 3-4A). In the absence of stimulation, CREB protein
expression was similar in WT and KO cells.
Microarray expression analysis was then utilized to curate target genes common
to PKA, CREB and cAMP activation pathways to determine if gene expression
downstream of CREB was altered in KO Leydig cells. A total of 38 genes were
identified (Table 3-1) and all showed strongly reduced expression in pre-pubertal and
adult KO Leydig cells (Figure 3-4B). These findings corroborated the results,
implicating the lack of Mrp4 in Leydig cells impairs LH mediated cAMP formation,
thereby disrupting CREB mediated transcription.
Genes directly involved in testosterone biosynthesis are downregulated in Mrp4 KO
Leydig cells
Initial analysis of a broad spectrum of genes related to steroid biosynthesis
showed striking similarities in the expression of affected genes in pre-pubertal and adult
KO Leydig cells (Figure 3-5). As our data revealed both cAMP concentration and
CREB phosphorylation to be impaired in KO Leydig cells, coupled with the fact that
genes involved directly in testosterone biosynthesis contain promoters with CREB
binding sites, expression of these specific genes were investigated. Real-time PCR
analysis of Leydig cell mRNA indicated a reduction in all testosterone biosynthesis genes
evaluated (Figure 3-6A). The most substantial decrease occurred with StAR expression
where a reduction of over 60% was observed. In contrast, minimal reduction of Pbr, the
second cholesterol importer, was seen in KO Leydig cells. Decreased mRNA expression
of Cyp11D1, Cyp17D1, and 3EHSD1 was also confirmed in this sample set. Protein
expression of these genes revealed a similar pattern of reduced expression in the KO
(Figure 3-6B) with the exception of Pbr. Of the mitochondrial proteins examined, StAR,
Pbr, and VDAC, only StAR was reduced. The decreased proteins levels of Cyp11D1 and
3EHSD1 were also consistent with the mRNA data, and these overall results reinforce the
findings of reduced testicular testosterone in Mrp4 KO mice.
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Figure 3-4. CREB phosphorylation and cAMP regulated genes are
downregulated in Mrp4 KO Leydig cells. (A) Immunoblot analysis of CREB and
phosphor-CREB (Ser133) at the indicated time points and treatment conditions. The
loading control was an unknown protein cross-reactive with the antibody that remained
constant among the samples. The graph at right shows ratio of phosphor-CREB to
CREB. (B) Selection of cAMP-regulated genes for query. The heat map represents
the gene expression in WT and KO Leydig cells.
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Table 3-1.

cAMP-, PKA-, and CREB-regulated genes in Leydig cells.

Gene Symbol
GLG1
BMP6
CLCN3
NRP1
PPP3CB
CTNNB1
YWHAB
GNA13
HDGF
ADCY9
MYLK
PPP1R8
KCTD12
MAP2K5
AKAP11
AKAP9
CREBBP
YWHAZ
CLCN6
ITPR1
PYGB
SMAD4
CHUK
YWHAG
H1F0
CLCN1
CREB1
KCTD3
PIK3R4
PPP1R12A
GRB2
ATF1
PPKAR1A
PLCG1
PPKD3

Gene Name
golgi apparatus protein 1
bone morphogenetic protein 6
chloride channel 3
neuropilin 1
protein phosphatase 3, catalytic subunit, beta isoform
catenin (cadherin associated protein), beta 1
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, beta polypeptide
guanine nucleotide binding protein, alpha 13
hepatoma-derived growth factor
adenylate cyclase 9
myosin, light polypeptide kinase
protein phosphatase 1, regulatory (inhibitory) subunit 8
potassium channel tetramerisation domain containing 12
mitogen-activated protein kinase 5
A kinase anchor protein 11
A kinase anchor protein 9
CREB binding protein
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, zeta polypeptide
chloride channel 6
inositol 1,4,5-triphosphate receptor 1
brain glycogen phosphorylase
MAD homolog 4 (Drosophila)
conserved helix-loop-helix ubiquitous kinase
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, gamma polypeptide
H1 histone family, member 0
chloride channel 2
cAMP response element binding protein 1
potassium channel tetramerization domain-containing protein 3
phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 4,
p150
protein phosphatase 1, regulatory subunit 12A
growth factor receptor bound protein 2
activating transcription factor 1
protein kinase, cAMP dependent regulatory, type I, alpha
phospholipase C, gamma-1
protein kinase D3
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Table 3-1.
Gene Symbol
ADD3
POLR2B
PDE3B

cont.
Gene Name
adducin 3 (gamma)
polymerase (RNA) II (DNA directed) polypeptide B
phosphodiesterase 3B, cGMP inhibited
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Figure 3-5. Steroid biosynthesis and related genes have a distinct expression
pattern in Mrp4 WT and KO mice. The expression of steroid biosynthetic genes in
pre-pubertal and adult Mrp4 WT and KO mice as examined by microarray analysis.
Hierarchical cluster was performed on ‘steroid’ genes curated from EntrezGene, Gene
Ontology and Metacore.
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Figure 3-6. Genes involved directly in testosterone biosynthesis are
downregulated in Mrp4 KO Leydig cells. (A) Real-time PCR analysis of
testosterone biosynthesis gene expression in Mrp4 KO Leydig cells (normalized to
GAPDH expression). (B) Immunoblot analysis of testosterone biosynthesis gene
expression. Vdac was used as a loading control. All error bars = SE.
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Acute Mrp4 inhibition results in elevated intracellular cAMP concentrations
The aforementioned results exhibited the importance of Mrp4 in regulating
normal testosterone biosynthesis; however, the reduced intracellular cAMP concentration
observed in the KO mice was still perplexing as cAMP is a substrate for Mrp4 [39]. As
Leydig cells in culture produce testosterone in a dose dependent manner upon LH
stimulation (Figure 3-7A) and also express testosterone biosynthesis proteins including
StAR and Cyp11D1 (Figure 3-7B), we utilized this system to examine the factors
resulting in decreased Mrp4 KO cAMP concentration.
Treatment of WT Leydig cells with 10 mIU LH resulted in increased testosterone
in the media in contrast to the unstimulated group. Inhibition of Mrp4 with 10uM
MK571 produced a sizeable decrease in testosterone concentration, similar to the
unstimulated cells (Figure 3-8A). Simultaneous measurement of intracellular cAMP
revealed concentrations were elevated greater than five-fold when Mrp4 was inhibited
(Figure 3-8B). Protein expression levels examined under these same conditions showed
both Lhr and StAR were downregulated when Mrp4 was inhibited while Cyp11D1
expression was not affected (Figure 3-8C). Analysis of other ABC transporters present
in the testes (Abcc1 and Abcg2) exhibited no change in expression levels when Mrp4 KO
Leydig cells are stimulated with LH (Figure 3-9).
Conclusions
Neither circulating LH nor cholesterol levels were altered between the Mrp4 WT
and KO mice; however, Leydig cell Lhr protein expression was downregulated in the KO
animal while key cholesterol biosynthesis genes were also decreased. Cyclic AMP
concentration was also decreased in KO Leydig cells in both the basal state as well as in
LH stimulated cells. CREB phosphorylation, a cAMP dependent event, was attenuated in
KO Leydig cells stimulated with LH and accordingly, downstream target gene expression
was decreased. In conjunction, mRNA and protein expression were decreased for several
key testosterone biosynthesis genes including Cyp11D1, Cyp17D1 and most crucial,
cholesterol importer, StAR.
In contrast with cAMP concentrations observed in the KO animal, acute inhibition
of WT Leydig cells in culture showed increased intracellular concentrations when
stimulated with LH. Both Lhr and StAR protein expression was decreased upon Mrp4
inhibition while Cyp11D1 protein was unchanged. No change in expression was
observed in other testes transporters when WT Leydig cells were LH stimulated.
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Figure 3-7. Cultured Leydig cells exhibit properties observed in vivo.
(A) Testosterone concentration in WT Leydig cells upon stimulation with various
concentrations of LH as measured by radioimmunoassay. (B) Immunoblot analysis of
testosterone biosynthesis genes in culture under indicated treatment conditions.
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Figure 3-8. Acute inhibition of Mrp4 results in increased intracellular cAMP
concentration but downregulated Lhr and StAR protein expression.
(A) Testosterone concentration in Mrp4 WT Leydig cells under the indicated treatment
conditions as measured by radioimmunoassay. (B) cAMP concentration in Mrp4 WT
Leydig cells as assessed by enzyme immunoassay. (C) Protein expression as determined
by immunoblot analysis in WT Leydig cells.
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Figure 3-9. Alternate ABC transporters are not upregulated upon LH
stimulation. Protein expression of Abcc1 and Abcg2 in Mrp4 WT and KO cultured
Leydig cells under the indicated conditions.
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CHAPTER 4. ADULT MRP4 KO MICE MAINTAIN A TESTICULAR
TESTOSTERONE DEFICIENCY WHILE POSSESSING NORMAL
TESTES MORPHOLOGY*
Introduction
Adequate testosterone concentration is required for the maintenance of normal
spermatogenesis although the absolute amount required is still unknown. Studies have
exhibited experimental testosterone reduction can lead to an abolition of sperm
production when testicular testosterone concentration is less than 20% of the controls
[152]. Hormonal removal has been shown to induce germ cell apoptosis [153] while the
presence of testosterone maintains spermatogenic homeostasis by inhibiting death signals
for germ cells [154]. Additionally, gonadotropin withdrawal in rodents has shown to
reduce the number of germ cells progressing through the multiple stages of
spermatogenesis [155].
Our data regarding pre-pubertal Mrp4 KO animals revealed reduced
intratesticular testosterone accompanied by impaired spermatogenesis, germ cell
proliferation and increased apoptosis. As KO mice are reproductively normal (discussed
in chapter 2), my goal was to characterize the adult mice testes in the same manner as
with the pre-pubertal animals in order to determine if all observed deficiencies were still
present.
Experimental Procedure
Immunohistochemistry
Whole testes and prostate were harvested from Mrp4 WT and KO mice and
immediately formalin fixed. Samples were submitted to the St. Jude Veterinary
Pathology Core where they were paraffin embedded and sectioned into 4 micron sections.
Following standard slide mounting procedure, the testes sections were stained with H&E
for analysis of overall testicular morphology. Additionally, testes were stained with an
antibody for the cell proliferation marker, Ki67, and for TUNEL, an antibody detecting
cell apoptosis. All staining was performed using the LabVision 720 autostainer (Thermo
Shandon).

________________________________________________________________________
* Modified with permission. Morgan JA., et al. Deregulated hepatic metabolism
exacerbates impaired testosterone production in Mrp4-deficient mice. J Biol Chem,
2012. 287(18): p. 14456-66 [138].
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Testicular testosterone measurement
Testicular testosterone concentration was measured from WT and KO mice by
harvesting testes, homogenizing in 1X PBS with a glass Dounce homogenizer, and
centrifuging at 5900 x g for 5 minutes at 4oC. The supernatant was then combined with
1ml diethyl ether, vortexed, and the organic phase was collected and dried down under a
stream of N2 at room temperature. The dried fraction was reconstituted in 0.2ml 1X PBS.
Testosterone concentration was then measured by an 125I-labeled RIA (MP Biomedicals)
according to the manufacturer’s instructions. Concentration of testicular testosterone was
expressed as ng/mg of testes weight.
Immunohistochemical counting
All IHC quantitation was performed on a minimum of three mice per age and
genotype group. Counts were taken on five random fields per slide at 40X magnification
on a Nikon Eclipse Ti microscope. For TUNEL and Ki67 staining, the cell was
considered positive if greater than 50% of the individual cell was stained.
Results
As a result of the findings from our pre-pubertal animals, it was imperative that
the same set of experiments were performed on the adult mice to determine if the
testicular testosterone deficiency persevered into adulthood. Most laboratory mouse
strains have a reported pubertal onset of 34-38 days after birth (online ref). To ensure
that sexually mature animals were being examined, mice greater than 8 weeks of age
were selected for analysis.
Adult Mrp4 KO mice had a six-fold reduction in testicular testosterone
concentration in comparison to WT mice (Figure 4-1). Despite reduced testosterone,
histological examination revealed readily detectable mature sperm cells in the
seminiferous tubule lumen (Figure 4-2A). In conjunction, germ cell proliferation was
equivalent among the genotypes as determined by Ki67 positive staining (Figure 4-2B).
Germ cell apoptosis was similar between the WT and KO animals (Figure 4-2C). These
data indicate that, despite decreased intratesticular testosterone levels, Mrp4 KO mice
have morphologically normal testes.
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Figure 4-1. Testicular testosterone is decreased in adult Mrp4 KO mice.
Testosterone concentration in adult Mrp4 WT (n = 7) and KO (n = 4) mice as measured
by radioimmunoassay. Error bars = SE.
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Figure 4-2. Testicular deficiencies are absent in the adult Mrp4 KO mouse.
(A) Testicular morphology as examined by H&E staining (20X magnification). Arrows
indicate mature sperm tail in the seminiferous tubule lumen. (B) Immunohistochemical
analysis of cell proliferation with Ki67 antibody. Graph below quantitates Ki67+ cells.
(C) Quantification of apoptotic cells by TUNEL positive staining. All error bars = SE.
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Conclusions
Adult Mrp4 KO mice showed greatly reduced testicular testosterone when
compared to WT animals but possessed a mature sperm cell population with normal germ
cell proliferation and minimal apoptosis.
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CHAPTER 5. DECREASED SERUM TESTOSTERONE IN PRE-PUBERTAL
MRP4 KO MICE RESULTS FROM INCREASED METABOLISM*
Introduction
The liver is the most important organ of steroid hormone metabolism. Biological
activities of hormones are not always reduced by steroid metabolism but can be rendered
inactive by metabolic conversion. Steroid molecules are eliminated from cells through an
array of enzymatic reactions followed by transport across the cell membrane. In the liver,
several categories of reactions occur that alter steroid hormone activity: hydroxylation,
conjugation, and oxido-reduction. The major metabolic pathway of steroids is through
hydroxylation by cytochrome p450 enzymes [114] which are expressed in almost every
tissue with the exception of skeletal muscle and red blood cells [156]. Several
constitutively expressed Cyp enzymes are involved in testosterone inactivation in a
regioselective and stereospecific manner [157] as they catalyze nicotinamide adenine
dinucleotide phosphate (NADPH) dependent monooxygenation of their hydrophobic
substrates [158]. The enzymatic reactions of testosterone hydroxylation include, but are
not limited to, hydroxylation at the following positions: 2D, 6D, 6E, 7D,16D, 16E, and
17E [120]. 6E-hydroxylation is the major route of NADPH dependent oxidative
metabolism, accounting for over 75% of the total hydroxylated metabolites generated by
human liver microsomes when testosterone, androstenedione or progesterone are used as
substrates [159].
Testosterone is primarily metabolized by members of the Cyp2 and Cyp3
families. Although human CYP3A4 (Cyp3a11 in mice) is generally regarded as the most
versatile enzyme involved in endogenous steroid metabolism [121], mouse Cyp2b10
(CYP2B6 in humans) plays an important role in testosterone metabolism. In vitro and in
vivo studies have shown Cyp2b10 and testosterone exist in a negative relationship [128,
130] as testosterone can suppress Cyp2b10 expression and vice versa.
Our preliminary data reveals serum testosterone concentration is decreased in prepubertal Mrp4 KO mice, but levels are restored to a more normal concentration once
these mice reach adulthood. My goal was to examine the potential mechanisms by which
testosterone concentration was reduced in these animals, mainly focusing on Cyp2b10
expression and activity.

________________________________________________________________________
* Modified with permission. Morgan JA., et al. Deregulated hepatic metabolism
exacerbates impaired testosterone production in Mrp4-deficient mice. J Biol Chem,
2012. 287(18): p. 14456-66 [138].
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Experimental Procedure
Serum testosterone measure ment
Serum testosterone was measured by collecting whole blood from Mrp4 WT and
KO mice and incubating at 4oC for 90 minutes in a microtainer collection tube (Becton
Dickinson). Samples were spun at 1200 x g for 90 seconds, serum was collected, and
testosterone was measured by 125I-labeled RIA (MP Biomedicals) per the manufacturer’s
instructions. Serum testosterone concentration is expressed as ng/ml.
Androstenedione measurement
Whole blood was collected by retro-orbital eye bleed from WT and KO mice,
incubated at 4oC for 2 hours, then centrifuged at 5900 x g for 5 minutes in order to
separate the serum from the remaining clotted blood. Androstenedione concentrations
were assayed from the serum by the Center for Research in Reproduction Ligand Assay
and Analysis Core at the University of Virginia School of Medicine (Charlottesville,
VA). Androstenedione concentration was measured by RIA, and the final concentration
was expressed in ng/ml.
Immunoblot analysis
Immunoblot analysis was performed in whole testes samples as described in
Chapter 2. Testes were probed for the following ABC transporters: Abcc1 (Abcam),
Abcb1 (Thermo Scientific), Abcg2 (Axxora), Abcc4 (M4I-10, a gift from Dr. George
Scheffer), and Abcc5 (M5I-10, a gift from Dr. George Scheffer). Actin (Sigma Aldrich)
was used as a loading control.
Liver microsomes were examined for protein expression of the following Cyps:
Cyp2b10, Cyp3a11 and Cyp1a2 (a gift from Dr. Erin Schuetz).
Immunohistochemistry
Whole prostate was harvested from Mrp4 WT and KO mice and immediately
formalin fixed. Samples were submitted to the St. Jude Veterinary Pathology Core where
they were paraffin embedded and sectioned into 4 micron sections. Following standard
slide mounting procedure, samples were stained with H&E for analysis of overall
prostate morphology. All staining was performed using the LabVision 720 autostainer
(Thermo Shandon).
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Real-time PCR
Real-time PCR was performed on whole liver samples from WT and KO mice
using 20ng of diluted cDNA with SYBR Green (Invitrogen) and 300 nM gene specific
primers using the ABI 7900HT sequence detection system (ABI). Primer sequences were
designed using Primer Express (ABI). The PCR protocol was as follows: 10 minutes
denaturation step, 40 cycles of two-step PCR (15 seconds at 95oC and 60 seconds at
60oC) followed by a dissociation step (15 seconds at 95oC, 15 seconds at 60oC and 15
seconds at 95oC). The fold difference in expression was normalized to the housekeeping
gene Gapdh and was calculated using the ''Ct method. The primer sequences utilized
were as follows: Cyp2b9 (sense, 5’- TGCTCAAGTACCCCCATGTCA-3’; antisense,
5’- AGAGAAAGTCCAAAAGGAGA-3’), Cyp2b10 (sense, 5’TCTTCCAACGTTCCCCATTG-3’; antisense, 5’- TCTTCCAACGTTCCCCATTG-3’),
Cyp7a1 (sense, 5’- AATGCACTTGGATCCTGAAATCTAC-3’; antisense, 5’TTCATCAAGGTACCGGTCGTATT-3’), Cyp7b1 (sense, 5’CGGCCCTGTTCCTCCTTAC-3’; antisense, 5’GATAAGGAAGCCAACCTTTTATCAAG-3’), Cyp3a11 (sense, 5’CCAAACCTCTGCCATTTTTAGG-3’; antisense, 5’GCACTCCATGTCGAATTTCCA-3’), Cyp3a13 (sense, 5’GCTGATGATAAACTCCCAGAATTACAA-3’; antisense, 5’CCAAAGAATCTCATAAAGC-3’) and Cyp1a2 (sense, 5’ATCCTTTGTCCCCTTCACCAT-3’; antisense, 5’- GGGAATGTGGAAGCCATTCA3’).
Microarray analysis
Analysis of liver gene expression used three mice per genotype and age group.
Samples were quality assessed as described in chapter 3 then processed using the
Affymetrix 3’ IVT express protocol. Labeled targets were hybridized on the HT_MG430_PM plate array and processed using the Gene-Titan system. Array signals were
summarized using the RMA algorithm with Affymetrix Expression Console software.
Cytochrome p450 targets were identified using Affymetrix Gene annotations while
transcriptional targets of AR and CAR were identified using curated terms from GeneGo
and Metacore pathways.
Liver microsome isolation
Approximately 50-100 mg liver samples from pre-pubertal and adult mice were
homogenized in homogenization buffer (100 mM Tris base, 100 mM KCl, 1 mM
ethylenediaminetetraacetic acid and 20 uM butylated hydroxytoluene) using a Potter
pestle attached to an electric drill motor. Samples were centrifuged at 18,500 x g for 15
minutes at 4oC, supernatant collected then spun at 106,000 x g for 60 minutes at 4oC.
The pelleted microsomal fraction was resuspended in microsomal storage buffer (100
mM potassium phosphate, 1 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, 20
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uM butylated hydroxytoluene and 20% glycerol). Microsome protein concentration was
determined using by the Bradford assay method.
Testosterone metabolite analysis
Mouse liver microsomes were suspended in 10 mM phosphate buffer (pH 7.4)
containing 10 mM MgCl2 and 2.4 mM NADPH. Testosterone was added (200uM final
concentration) followed by a 60 minute incubation at 37oC. The reaction was terminated
by the addition of an equal volume of cold methanol and precipitated proteins were
separated by centrifugation at 13000 x g for 5 minutes at room temperature. One hundred
microliters of sample were injected into the HPLC system for metabolite analysis. HPLC
was performed using the Waters 500-717-2487 systems (Waters) and chromatographic
separation was achieved using a reverse phase Hibar RT 250-4 pre-packed column
(Merck). The mobile phase was 50% methanol, 50% water (v/v) with a run time of 50
minutes. Data acquisition and analysis was performed using Empower 2 software. The
rate of formation of each metabolite is expressed at picomole/mg/min. The following
standards were used: 6D-hydroxytestosterone, 6E-hydroxytestosterone, 16Dhydroxytestosterone, 16E-hydroxytestosterone, and 7D-hydroxytestosterone (Steraloids,
Inc.)
Liver testosterone measurement
Liver samples were harvested from pre-pubertal and adult WT and KO mice, and
testosterone was extracted and measured as described in chapter 2.
PROD assay
Approximately 20 ug of liver protein extract was combined with 0.2ml Buffer A
(1.25 mM ethylenediaminetetraacetic acid, 1 mg/ml bovine serum albumin, 10 uM
dicumerol, 4 uM 7-pentoxyresorufin, and 40 mM Tris pH 8.3). Samples were incubated
for 1 minute at 37oC, and the reaction was started by the addition of 25ul of 10 mM
NADPH. The mixture was incubated for 5 minutes at 37oC, and the reaction was stopped
by adding .25 ml ice cold methanol. Samples were then spun at 5900 x g at 4oC.
Florescence was read at an excitation/emission spectra of 558/590.
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Results
Serum testosterone concentration is drastically reduced in pre -pubertal Mpr4 KO
mice but is restored with age
Measurement of serum testosterone concentration in pre-pubertal Mrp4 KO mice
revealed an approximate 90% reduction when compared to Mrp4 WT animals
(Figure 5-1A). Interestingly, upon reaching adulthood, serum testosterone levels were
relatively normal between the genotypes (Figure 5-1B). Circulating androstenedione
concentrations were similar between the genotypes at both ages (Figure 5-1C), indicating
the adrenal gland was not affecting the observed serum testosterone concentration.
Additionally, immunoblot analysis of adult adrenal glands revealed no major alterations
in StAR or Pbr protein expression, suggesting the increased serum testosterone in KO a
mouse is not a result of increased testosterone biosynthesis in the adrenal glands
(Figure 5-2). To confirm that circulating testosterone was significantly altered in prepubertal KO animals, prostate morphology was examined as the prostate requires
exogenous testosterone for maturation [160]. Immunohistochemical analysis showed
impaired prostate maturation in the pre-pubertal KO mouse, exhibiting disorganized
tubular structure and enlarged interstitial space (Figure 5-3A) as compared to its WT
counterpart. By adulthood, when serum testosterone levels were similar between the
genotypes, prostate morphology was indistinguishable (Figure 5-3B), representative of a
normal circulating testosterone concentration.
Additional ABC transporters expressed in the testes are not unregulated in the
Mrp4 KO mouse
As other ABC transporters are expressed in the testes and interact with steroids
which are structurally similar to testosterone [161], we examined their expression in adult
testes to determine if that may account for the rise in serum testosterone in KO mice. All
inspected transporters (Abcc1, Abcb1, Abcg2 and Abcc5) showed no increase in protein
expression in these animals (Figure 5-4A). Abcc2 expression was undetectable.
Likewise, real-time PCT analysis of Slco6b1 and Slco6c1, reported androgen efflux
transporters [162] showed no upregulation in Leydig cells (Figure 5-4B). These findings
suggested the rise in circulating testosterone concentration in the adult KO mouse was
not a product of increased expression of steroid efflux transporters.
Decreased serum testosterone in pre -pubertal Mrp4 KO mice is a result of increased
testosterone metabolism by Cyp2b10
Microarray analysis of pre-pubertal liver samples of Mrp4 WT and KO mice
showed increased Cyp2b10 expression in KO mice as compared to WT. Expression
levels returned to those seen in WT mice once the KO mice reached adulthood. Other

55

Figure 5-1. Serum testosterone concentration is decreased in the pre -pubertal
Mrp4 KO mouse but normalizes with age. (A) Serum testosterone concentration in
pre-pubertal Mrp4 mice as measured by radioimmunoassay (WT, n = 7; KO, n = 10).
(B) Serum testosterone concentration in adult Mrp4 mice as measured by
radioimmunoassay (WT, n = 10; KO, n = 15). (C) Serum androstenedione
concentration in adult mice assessed by radioimmunoassay (n = 2 mice/genotype). All
error bars = SE.
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Figure 5-2. Protein expression of cholesterol importers are not decreased in Mrp4
KO adrenal glands. Expression of StAR and Pbr in Mrp4 WT and KO mouse adrenal
glands as determined by immunoblot assay.
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Figure 5-3. Pre-pubertal Mrp4 KO mice exhibit impaired prostate morphology
while adult KO mice are normal. Prostate gland morphology of (A) pre-pubertal and
(B) adult Mrp4 mice. (H&E, 400X magnification)
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Figure 5-4. Alternate ABC and steroid transporters are not upregulated in Mrp4
KO mice. (A) Immunoblot analysis of ABC transporters in adult testes. E-actin was
used as a loading control. (B) mRNA expression of Slco6b1 and Slco6c1 in KO Leydig
cells analyzed by real-time PCR, normalized to Rsp16 expression.
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testosterone metabolizing Cyps (Cyp1a2, Cyp2b9, Cyp3a11, Cyp3a13, Cyp7a1 and
Cyp7b1) did not exhibit the same pattern of expression as Cyp2b10 (Figure 5-5). In
accordance with the microarray data, real-time PCR confirmed Cyp2b10 expression was
elevated in pre-pubertal Mrp4 KO liver microsomes but returned to a comparable level
with the WT at an adult age (Figure 5-6A). Upregulated liver microsome Cyp2b10
protein expression was observed in individual KO mice versus expression in WT mice,
Cyp2b10 expression was variable in adult animals regardless of genotype. Protein
expression of Cyp3a11 increased with age but was not altered between the WT and KO
samples in either age group. Cyp1a2 protein levels were consistent regardless of age or
Mrp4 status (Figure 5-6B).
In addition to analyzing Cyp2b10 expression, catalytic activity was also
examined. Total Cyp2b activity, as assessed by pentoxyresorufin O-dealkylase (PROD)
assay, in pre-pubertal KO samples was elevated when compared to the WT. This was not
observed in adult mice (Figure 5-7A). Correspondingly, increased formation of
hydroxylated testosterone metabolites was detected with an approximate 60% increase in
metabolites observed in the pre-pubertal Mrp4 KO mice (Figure 5-7B). This data is in
accordance with the PROD results.
Liver testosterone concentration was then measured to validate the results seen
with increased Cyp2b10 expression and catalytic activity. In accordance with the
previous results, testosterone levels in pre-pubertal Mrp4 KO mice were substantially
reduced when compared to the corresponding WT animals. No difference in testosterone
concentration was observed in adult mice (Figure 5-8).
Elevated Cyp2b10 expression is not a result of general CAR activation
To further verify Cyp2b10 expression was determinant on testosterone
concentration and not other regulatory factors that modulate Cyp2b10, several factors
were assessed. Real-time PCR analysis revealed similar AR mRNA expression in prepubertal livers (Figure 5-9A); however, expression of AR target genes was largely
downregulated in the KO mouse (Figure 5-9B). This decreased activation is consistent
with decreased testosterone concentration in these animals.
In vivo studies have shown that testosterone suppresses Cyp2b10, possibly by
suppressing CAR activity [163]. Gene expression analysis of CAR target genes in prepubertal mice revealed that only Cyp2b10 is strongly upregulated in Mrp4 KO mice
(Figure 5-10) indicating the general de-repression of CAR cannot explain the increased
Cyp2b10 upregulation in KO liver.
Conclusions
Serum testosterone concentrations were found to be greatly reduced in the prepubertal KO animal but increased to a more normalized level upon reaching adulthood.
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Figure 5-5. Cyp2b10 RNA expression is upregulated in pre-pubertal Mrp4 KO
mice but decreases at an adult age. Expression heat map of all Cyp450 genes in the
liver. Enlarged map shows testosterone metabolizing Cyp450s only (n = 3 mice per age
and genotype). Expressed as change compared to WT values.
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Figure 5-6. Both mRNA and protein expression of Cyp2b10 are elevated in prepubertal Mrp4 KO mice but decrease in adulthood. (A) Hepatic expression of
testosterone metabolizing enzymes in pre-pubertal and adult Mrp4 KO mice (n = 3 mice
per age and genotype group). Real time-PCR data is normalized to Gapdh expression
and presented as the ratio of expression compared to WT mice. (B) Representative
immunoblot analysis of Cyp2b10 and Cyp3a11 proteins in liver microsomes (n = 3 mice
per age and genotype.) Cyp1a2 was used as a loading control. Mean ratios of band
intensity from two separate experiments are graphed to the right using ImageJ software.
All error bars = SE.
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Figure 5-7. Testosterone metabolism is increased in pre-pubertal Mrp4 KO
animals. (A) Cyp2b enzyme activity in liver microsomes determined by PROD assay.
(B) Measurement of hydroxylated testosterone metabolites from liver microsomes using
HPLC analysis (n = 3 mice per age and genotype). Cyp450s in parenthesis represent the
major Cyp responsible for the corresponding metabolite. All error bars = SE.
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Figure 5-8. Liver testosterone concentration is decreased in pre-pubertal
KO mice compared to WT. Total testosterone concentration in pre-pubertal and
adult Mrp4 mouse liver as measured by radioimmunoassay (n = 4 mice per age and
genotype). Error bars = SE.
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Figure 5-9. Androgen receptor target genes are downregulated in pre-pubertal
Mrp4 KO mice. (A) Hepatic androgen receptor mRNA expression assessed by real-time
PCR normalized to Gapdh expression. (B) Heat map representing the expression of
androgen receptor targets in pre-pubertal Mrp4 KO mice in relation to WT expression
levels.

65

Figure 5-10. A general downregulation of Car target gene expression is not
observed in pre -pubertal Mrp4 KO mice. Heat map representing hepatic gene
expression of Car target genes in pre-pubertal KO mice in relation to WT gene
expression.
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Confirmation of these effects was seen upon examination of prostate morphology, an
organ which requires circulating testosterone for maturation. Pre-pubertal KO prostate
presented with a disorganized structure and excess interstitial space while the adult KO
prostate was identical to the WT. Circulating androstenedione concentrations were not
altered between the genotypes, and upregulation of other ABC transporters present in the
testes was not observed.
Increased Cyp2b10 expression and activity was confirmed in the pre-pubertal KO
mice. No other testosterone metabolizing Cyp examined exhibited this increase. Upon
reaching an adult age, Cyp2b10 in KO mice showed a considerable decrease in both
expression and activity. This metabolizing effect was also confirmed by liver
testosterone levels which showed the same pattern as serum testosterone. Finally, the
change in Cyp2b10 expression was not a result of CAR activation as it was the only
target gene upregulated in our analysis, confirming its expression levels are dependent on
testosterone concentration in this system.
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CHAPTER 6.

DISCUSSION

Mrp4 Is Localized to Leydig Cells
Prior to our initial experiments, Mrp4 was well reported to have testicular
expression; however, its cellular localization and specific role had yet to be determined
[136, 137]. Through the use of immunoblot and immunohistochemical techniques, Mrp4
was discovered to be specifically localized to the Leydig cell compartment. Leydig cells
are responsible for the synthesis and release of the primary male sex hormone
testosterone [57] which is vital for the maintenance of spermatogenesis [164].
While it has been shown that ABC transporters expressed in the testes play their
expected cytoprotective role in effluxing toxic compounds as indicated by the protective
role of Mrp1 at the blood-testes barrier [140], data has also been presented which
highlights the importance of these transporters in regulating testosterone levels. In
addition to the previously discussed testosterone deficiency observed in Abcc1 KO
animals, ABCA1 KO mice also exhibit reduced intratesticular testosterone levels.
Primarily expressed in Sertoli cells, the absence of ABCA1 results in abnormal lipid
accumulation in Sertoli cells and depletion of lipid droplets from Leydig cells, producing
partially compromised Leydig cell function [165]. However, no evidence had been
presented directly linking the loss of Mrp4 to testosterone deficiency. Interestingly,
substrates of Mrp4 had been implicated in negatively impacting androgen response. In
vivo analysis of chronic methotrexate treatment in rats showed decreased testosterone as
compared to untreated controls. Two enzymes involved in the steroid biosynthesis
pathway, 17EHSD and 3EHSD both showed decreased activity [166]. Likewise, aspirin,
both a substrate and inhibitor of Mrp4 [167, 168] has been reported to impact
steroidogenesis. Acute aspirin administration in humans showed impaired
steroidogenesis, a phenomenon most likely due to aspirin’s interference with LH-hCG
action on the plasma membrane of Leydig cells [169]. Aspirin dosing in rodents resulted
in decreased spermatid numbers, producing a morphology consistent with impaired germ
cell maturation [170, 171]. With initial data confirming the localization of Mrp4 to
Leydig cells, coupled with literature evidence supporting that inhibition of Mrp4 impairs
steroidogenesis and spermatogenesis, it was hypothesized that Mrp4 deficient mice may
possess an inherent defect in testosterone production.
Mrp4 KO Mice Have an Inherent Deficiency in Testicular Testosterone
Concentration
Intratesticular testosterone measurements revealed severely impaired levels in
Mrp4 KO animals both prior to puberty and at an adult age. To confirm these results, a
series of testosterone dependent parameters were observed. Pre-pubertal Mrp4 KO mice
possessed half the number of primary spermatids within the seminiferous tubules than did
the WT mouse, consistent with low availability of testosterone [143, 172]. Germ cell
maturation is controlled by a balance of cell proliferation and apoptosis [144, 153], and
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pre-pubertal KO mice exhibited decreased germ cell proliferation and increased
apoptosis. These findings are consistent with previous studies that illustrate gonadotropin
deprivation and/or testosterone withdrawal results in increased apoptosis at multiple
stages of germ cell development [173, 174]. However, despite the continued reduction in
testicular testosterone concentration in adult Mrp4 KO mice, proliferation and apoptosis
measurements were comparable to those seen in Mrp4 WT animals. We sought an
explanation for the restoration of testicular morphology in adult KO mice despite their
sustained testosterone reduction.
It is well documented that testosterone is essential for spermatogenesis, although
the absolute levels required are still debatable. In rodents and primates, intratesticular
testosterone levels are elevated approximately 100 fold over serum concentrations by
virtue of its localized production. These concentrations are in excess if what is required
to saturate the AR [175]. Experimental reduction of testicular testosterone levels in rats
led to an abolition in sperm production when the concentration was less than 20% of that
of the controls [152]. This proportionate reduction was observed in the pre-pubertal and
adult Mrp4 KO mice, but only the younger animals exhibited signs of impaired
spermatogenesis. Critical analysis of testosterone concentration in KO mice revealed a
four-fold increase in testosterone levels as the mice reached adulthood. While the
concentration remains decreased in adult KO mice, it is conceivable that the four fold
increase generates enough testicular testosterone to saturate the AR in the testes, thus
allowing normal progression of spermatogenesis in these animals.
In conclusion, our initial studies revealed the localization of Mrp4 to the Leydig
cells. Additionally, it was observed the loss of Mrp4 resulted in decreased intratesticular
testosterone in these animals, but this deficiency negatively impacted mice before
puberty. As adult mice possessed normal testicular morphology and were reproductively
comparable to the WT animals with respect to litter size, it appeared the loss of Mrp4 did
not contribute to an overall detrimental phenotype in the adult KO testes.
Cyclic AMP Is the Regulatory Factor Controlling Decreased Testosterone Synthesis
in the Mrp4 KO Mouse
The data presented in this section provided the first evidence that the absence of
Mrp4 in the testes resulted in an inherent defect in Leydig cell testosterone biosynthesis.
While prior studies had demonstrated the loss of a testicular transporter resulted in
impaired intratesticular testosterone concentration, the mechanism underlying the
decrease had failed to be fully characterized or was not dependent on the transporter’s
expression in the Leydig cells. We provided evidence that the testicular testosterone
deficiency characterized in the Mrp4 KO mouse was a product of decreased intracellular
cAMP concentration, leading to a downstream cascade of impaired biosynthetic
processes, including CREB phosphorylation and diminished testosterone biosynthetic
gene expression.
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Proper regulation of cAMP is critical for the maintenance of testosterone biosynthesis, as
it is a primary regulator of many steps in testosterone formation. Luteinizing hormone
receptor mRNA expression requires basal cAMP expression [99]. However, long-term
incubation of the MA-10 Leydig cell line with a cAMP derivative resulted in decreased
LHR mRNA [100], presumably due to increased receptor degradation by receptormediated endocytosis. While this may initially appear to be inconsistent with our data
showing decreased cAMP concentration, acute LH stimulation of Leydig cells generated
an increase in intracellular cAMP levels in the Mrp4 KO. It can be surmised that this
initial accumulation of cAMP potentially triggers receptor internalization, resulting in
decreased Lhr expression observed in Mrp4 KO Leydig cells.
Cyclic AMP also modulates a variety of aspects of testosterone biosynthesis
through its binding and activation of CREB. CREB mediated gene transcription is
achieved by activation of PKA and subsequent phosphorylation of CREB. In turn, CREB
binds the conserved cAMP response element TGACGTCA typically found in the
promoter of many cAMP responsive genes [102]. Multiple genes in the testosterone
biosynthesis pathway contain CREB binding sites in their promoter regions. The
activation of the StAR protein, the rate limiting step in steroid biosynthesis, is dependent
on cAMP. The StAR promoter does not contain the typical CRE binding motif but
instead contains a cAMP responsive region that has functional elements for other
transcriptional activities [103]. Despite the absence of a consensus CRE site, studies
have shown the classical cAMP-PKA signaling cascade activates CREB and upregulates
the transcription of the StAR gene [104, 105]. StAR expression is vital for steroid
biosynthesis as shown in cell culture context as well as with a StAR KO mouse model.
Mice lacking StAR exhibited Leydig cell hyperplasia and a reduced capacity for
spermatogenesis [44], indicating these animals possess insufficient androgen production
to maintain optimal spermatogenesis.
Our results in Mrp4 KO mice reveal both a decrease in cAMP concentration as
well as lowered StAR mRNA and protein expression. Although the phosphorylation
status of StAR has yet to be determined, based on prior reports, the Mrp4 KO animal
could potentially possess a deficiency in StAR phosphorylation due to lowered cAMP
concentration and possible decreased PKA activation. In addition to CREB binding,
cAMP responsiveness of the StAR promoter is also regulated by SF-1 [176] which has
been identified as essential to both basal and hormone induced cAMP regulation of StAR
[177, 178]. Microarray analysis of whole testes revealed a slight decrease in SF-1
expression in KO animals (data not shown) thereby adding another factor that could
account for the decreased StAR expression observed in these animals.
The concurrent cholesterol importer, Pbr, is not reported to be under CREB
activation; however, a cAMP–inducible element that regulates Pbr structure and function
is present as inhibition of PKA results in reduced steroid formation in MA-10 cells [108].
Functionally, Pbr exists in a complex with other proteins including VDAC, ANT, pk10,
PRAX-1 and PAP7 [179]. We observed no downregulation of either Pbr or Vdac protein
expression in Mrp4 KO testes in spite of reduced cAMP concentration, indicating the Pbr
complex may be regulated by other crucial factors. It has been suggested that Pbr may
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play a role in controlling the import of StAR into the mitochondria as Leydig cells with
knocked down Pbr expression generated low formation of mature StAR protein in
response to hormone stimulation, correlating with an absence of steroid formation [95].
For our studies it may be inferred, in the presence of impaired cAMP concentration and
StAR expression, the equivalent expression of Pbr in Mrp4 WT and KO testes is
responsible for the observed testicular testosterone, albeit minimal, concentration in these
mice.
For CREB induced gene expression, the duration of Ser133 phosphorylation has
been shown to determine the efficacy of expression. In a subtype of striatal neurons,
stimulation with dopamine, a cAMP activating neurotransmitter, involves Ser133
phosphorylation that is maintained 30 minutes after stimulation. In other subtypes of
striatal neurons, Ser133 phosphorylation is more transient as dephosphorylation occurs
within 15 minutes of the stimulus. In neurons where phosphorylation is sustained, CREB
target genes are induced whereas unsustained phosphorylation does not promote gene
induction [111]. These results bolster our data that exhibits minimal Ser133
phosphorylation in Mrp4 KO Leydig cells stimulated with LH. After 30 minutes
exposure to hormonal stimulation, the phosphorylation state of these cells was barely
altered above the basal level. As illustrated with neuronal cells, this non-existent Ser133
phosphorylation in Mrp4 KO Leydig cells produced a host of inactivated downstream
gene targets.
The decrease in cAMP concentration measured in Mrp4 KO Leydig cells was
initially a puzzling finding as it was anticipated cAMP levels would be elevated as it is a
well-established substrate for Mrp4. More detailed analysis revealed, however, that acute
inhibition of Mrp4 when stimulated with LH resulted in increased intracellular cAMP
accumulation in the WT cells. As the activation of adenylyl cyclase and the formation of
cAMP occurs within seconds of receptor activation [180], it can be postulated that the
decreased cAMP concentration in KO Leydig cells is not a result of abated formation but
instead of increased degradation by PDEs. Phosphodiesterases including PDE4A [181],
PDE5A [182], PDE8A [148] and PDE8B [183] have been localized to the testes. Both
PDE8A and PDE8B are highly expressed in Leydig cells, and their inhibition increases
PKA-dependent phosphorylation and protein expression of components of
steroidogenesis [183]. The same experiments have also shown additional inhibition of
PDE4 synergize potentiated steroid production, demonstrating these PDEs function to
maintain low cAMP levels thereby suppressing steroidogenesis. While PDE status has
yet to be clarified in our experiments, based on our data, increased PDE concentrations
may be responsible for the long-term depression of cAMP concentration detected in
Mrp4 KO Leydig cells. Our future studies aim to examine this more in depth.
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Increased Cyp2b10 Expression and Activity Results in Decreased Serum
Testosterone in Pre -pubertal Mrp4 KO Mice
Our results from these sets of experiments highlight the important relationship
between testosterone concentration and Cyp2b10 expression. Initial findings of
decreased serum testosterone concentration in pre-pubertal Mrp4 KO mice but
normalized adult levels were originally a perplexing result. Although testicular
testosterone biosynthesis was reduced regardless of age (refer to chapters 2 and 4), it was
not anticipated that its release from the testes impacted circulating concentrations, as
testosterone is not a substrate for Mrp4 [54]. While the common route for testosterone
release is generally accepted to be passive diffusion [64], androgen efflux proteins have
been characterized. The rat gonad specific transporters Slco6a1 and Slco6b1 transport
DHEAS [162] while Abcg2 effluxes steroids including estradiol, progesterone, and
testosterone [148]. Similarly, ABC transporters ABCG1 and ABCG5 have been
implicated in cholesterol transport [184, 185]. Our samples were evaluated for
expression of some of these transporters to determine if increased expression in adult
Mrp4 KO mice could be responsible for elevated serum testosterone concentration. As
our results revealed that none of the transporters showed upregulation in the KO, it was
concluded that increased serum testosterone was not a result of potentially increased
transport.
Based on published reports stating testosterone concentration and Cyp2b10
expression have a negative correlation, we proposed decreased serum testosterone in prepubertal KO mice was a result of increased Cyp2b10 expression and catalytic activity.
Results from microarray analysis and real-time PCR showed increased Cyp2b10
expression in KO mice. Likewise, elevated Cyp2b10 protein expression was observed in
pre-pubertal Mrp4 KO liver microsomes. Although Cyp3a11 is an important
testosterone metabolizing enzymes, no change in expression was ever observed in our
samples. Unlike with Cyp2b10, there is no current evidence that Cyp3a11 expression
depends on testosterone concentration. The adult samples did show the expected increase
in expression regardless of genotype [113, 186]. Consistent with the expression data,
Cyp2b10 catalytic activity was elevated in the pre-pubertal KO mice. Increased 16D- and
16E-hydroxylated metabolites were consistent with elevated Cyp2b10 activity, as they
are primarily metabolized by the enzyme [124, 125].
The actions of testosterone and other androgens are mediated through the AR, a
ligand dependent transcription factor. Upon entry into the androgen target cell,
testosterone either binds directly to the AR or binds following its conversion to DHT.
Following a series of conformational changes, activation or repression of downstream
target genes occurs [187]. Our microarray analysis of pre-pubertal Mrp4 KO liver
showed AR target genes were largely downregulated in comparison to WT, compatible
with reduced liver testosterone concentrations. Based on these results, it is conceivable
to speculate DHT concentrations were similarly reduced in these animals although levels
were not measured.
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Studies have shown endogenous androgens repress the nuclear orphan receptor
CAR, of which Cyp2b10 is a target gene [163]. We aimed to test if general de-repression
of CAR target genes was secondary to reduced hepatic testosterone in pre-pubertal KO
mice. The gene expression pattern was similar between the genotypes with the exception
of strongly induced Cyp2b10 expression in the KO liver. Therefore, general derepression of CAR could not explain the increased hepatic Cyp2b10 in pre-pubertal KO
mice.
In conclusion, these studies show reduced systemic testosterone concentration in
pre-pubertal Mrp4 KO mice is a result of increased metabolism by Cyp2b10 and
decreased testicular testosterone production However, in adult mice, circulating
testosterone concentration returns to near normal levels despite a sustained reduction in
testicular testosterone due to alleviated testosterone metabolism.
Genetic Variants Highlight the Importance of Proper Functioning Mrp4
The data shown here provides the first evidence that the absence of Mrp4 in a KO
mouse model results in the downregulation of a steroid biosynthetic pathway. However,
several human mutations of MRP4 have been identified, with some creating detrimental
effects due to lack normal MRP4 function. Studies conducted in Xenopus laevis oocytes
expressing the human MRP4 missense mutation V776I revealed a decreased ability of
these oocytes to transport 6-mercaptopurine (6MP). In conjunction with decreased
transport, the V776I mutation also exhibited reduced protein expression as well as plasma
membrane surface expression [188]. Similar types of studies performed in HEK293 cells
also reinforced the importance of properly functioning MRP4. For this report, an
ethnically diverse population (270 healthy individuals) was used to obtain potential
MRP4 variants in the general population. A total of 98 variants were identified, and ten
were chosen for analysis based on a frequency of ≥5% in the population studied. While
none of the variants were observed to be completely deleterious, both G187W and
G487E, both evolutionarily conserved, exhibited significantly reduced ability to transport
both azathioprine (AZA) and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA). The
P78A and P403L variants, also evolutionarily conserved, showed reduced function when
transporting AZT [189]. A single nucleotide polymorphism (rs3765534) found in human
MRP4, common in approximately 18% of the Japanese population, renders cells more
susceptible to 6MP toxicity than cells with WT MRP4. This variant allele showed
similar protein expression when transfected into HEK293 cells but strongly reduced cell
surface expression, a factor that contributes to increased intracellular thioguanine
nucleotide concentration [45]. Based on these and other data, it can be hypothesized that
naturally occurring MRP4 variants, in addition to contributing to chemotherapeutic
toxicity, may also play a role in reducing testosterone concentration in human males.
Although this has yet to be examined, it merits investigation in order to fully understand
the crucial role of MRP4 in the testes.
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Future Directions
The complete set of studies presented here show Mrp4 is a crucial factor in
regulating normal testosterone biosynthesis. We anticipate future studies based on this
work will highlight the importance of Mrp4 expression in Leydig cells as it relates to
chemotherapeutic drug induced male sterility. Multiple cancer chemotherapeutic drugs
produce detrimental reproductive effects secondary to impaired testosterone production.
Chronic administration of azathioprine and methotrexate have been lined to sperm
toxicity [190] and decreased testosterone concentration [166], respectively, in rodents. 6mercaptopurine, a routinely administered drug in both childhood [191] and adult [192]
acute lymphoblastic leukemia, is reported as a carcinogen [193] that negatively impacts
reproductive capabilities [194]. These studies all conclude the adverse reproductive
effects are a result of decreased testosterone concentration. We anticipate Mrp4 protects
Leydig cells from chemotherapeutic toxicity caused from these agents through its ability
to both efflux these substrates as well as maintain normal testosterone biosynthesis.
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